WO2011146725A1 - Biomarkers for a multikinase inhibitor - Google Patents

Biomarkers for a multikinase inhibitor Download PDF

Info

Publication number
WO2011146725A1
WO2011146725A1 PCT/US2011/037166 US2011037166W WO2011146725A1 WO 2011146725 A1 WO2011146725 A1 WO 2011146725A1 US 2011037166 W US2011037166 W US 2011037166W WO 2011146725 A1 WO2011146725 A1 WO 2011146725A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
level
cell
ck18m30
regorafenib
Prior art date
Application number
PCT/US2011/037166
Other languages
French (fr)
Inventor
Michael Jeffers
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of WO2011146725A1 publication Critical patent/WO2011146725A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the invention relates generally to cancer and biomarkers, and more particularly to identification of clinically useful serum (plasma treatment) and/or tumor biomarkers and expression signatures that can be used for prognostication and guidance for the treatment of cancer patients, such as patients with renal cell carcinoma (RCC), with a multikinase inhibitor, such as, for example, Regorafenib (solely or in combination with other agents).
  • plasma treatment clinically useful serum
  • tumor biomarkers and expression signatures that can be used for prognostication and guidance for the treatment of cancer patients, such as patients with renal cell carcinoma (RCC), with a multikinase inhibitor, such as, for example, Regorafenib (solely or in combination with other agents).
  • Renal cell carcinoma is the most common type of kidney cancer in adults and is one of the most lethal tumors. Where the tumor is confined to the renal parenchyma, the 5- year survival rate is 60-70%, but this is lowered considerably where metastases have spread. As such, there is a strong need for advancement in prognosis, early detection, and treatment of RCC.
  • Diaryl urea compounds such as Regorafenib, 4 ⁇ 4-[3-(4-chloro-3- trifluoromethylphenyl)-ureido] -3 -fluorophenoxy ⁇ -pyridine-2-carboxylic acid methylamide, and its derivatives as described for example in US 20050038080, are potent anti-cancer and anti-angiogenic agents that possess various activities, including inhibitory activity on the VEGFR, PDGFR, raf, p38, and/or flt-3 kinase signaling molecules.
  • diaryl urea compounds have been previously characterized as having various activities, including for inhibiting the Raf/MEK ERK pathway, raf kinase, p38 kinase, VEGFR kinase, PDGFR kinase. These activities and their use in treating various diseases and conditions are disclosed in, e.g., WO 2005/009961.
  • Regorafenib is an investigational anti-cancer drug with a distinct profile targeting angiogenic (VEGFR, TIE-2), stromal (PDGFR) and oncogenic (RAF, RET and c-KIT) receptor tyrosine kinases.
  • US Patent 7,833736 discloses ten protein biomarkers: Heat Shock Protein-27 (HSP- 27), Cortactin, Cdc25C (or phospho-Cdc25C (Ser216 or Thr48)), phospho-MAPKAPK-2 (Thr334), phospho-Cyclin E (Thr62), Stathmin, phospho-ATF2 (Thr69 or Thr71), phospho- Histone H3 (Thr3), phospho-EIF-4B (Ser422), and phospho-Rpbl (Ser2 or Ser5), that are said to predictive of cancer resistance or responsiveness to targeted inhibitors of certain Receptor Tyrosine Kinases (RTKs).
  • HSP- 27 Heat Shock Protein-27
  • Cortactin Cdc25C
  • Cdc25C or phospho-Cdc25C (Ser216 or Thr48)
  • phospho-MAPKAPK-2 Thr334)
  • phospho-Cyclin E Thr62
  • Stathmin phospho-ATF2 (
  • kits for identifying the resistance or responsiveness of certain cancers, tumors, and patients to these inhibitors which comprise detectable reagents for three or more of the 10 biomarker proteins. It is said the kits can be employed on biopsy samples, fine needle aspirates, or biological fluids such as serum, blood plasma, or bone marrow, and may comprise whole cells or a cell lysate, whether or not isolated.
  • the present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment.
  • this invention relates to the use of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF as biomarkers for efficacy of treatment with diaryl urea multikinase inhibitors such as Regorafenib.
  • sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF decreased in subjects treated with Regorafenib, while PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, or ANG2 levels increased.
  • these markers can be used to determine the efficacy of Regorafenib treatment.
  • Another embodiment of the present invention is a method for screening the effects of a drug on a tissue or cell sample comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels in the tissue or cell sample are analyzed before and after exposure to the drug, and a variation in the expression level of the gene and/or gene product is indicative of a drug effect or provides a patient diagnosis or predicts a patient's response to the treatment.
  • the drug is a Regorafenib.
  • the gene or gene product is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF, and soluble forms thereof.
  • the invention further provides a method for identifying a compound useful for the treatment of cancer comprising administering to a subject with cancer a test compound, and measuring the activity of the polypeptide, wherein a change in the activity of the polypeptide is indicative of the test compound being useful for the treatment of cancer.
  • the polypeptide is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof (e.g., detection of shed VEGFR2), and in another embodiment, the compound is a Regorafenib.
  • the invention provides methods which may be used to identify compounds which may act, for example, as regulators or modulators such as agonists and antagonists, partial agonists, inverse agonists, activators, co-activators, and inhibitors. Accordingly, the invention provides reagents and methods for regulating the expression of a polynucleotide or a polypeptide associated with cancer.
  • Reagents that modulate the expression, stability, or amount of a polynucleotide or the activity of the polypeptide may be a protein, a peptide, a peptidomimetic, a nucleic acid, a nucleic acid analogue (e.g., peptide nucleic acid, locked nucleic acid), or a small molecule.
  • the present invention also provides a method for providing a patient diagnosis comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels of normal and patient samples are analyzed, and a variation in the expression level of the gene and/or gene product in the patient sample is diagnostic of a disease.
  • the patient samples include, but are not limited to, blood, amniotic fluid, plasma, semen, bone marrow, and tissue biopsy.
  • the gene or gene product is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof.
  • the present invention still further provides a method of diagnosing cancer in a subject comprising measuring the activity of the polypeptide in a subject suspected of having cancer, wherein if there is a difference in the activity of the polypeptide, relative to the activity of the polypeptide in a subject not suspected of having cancer, then the subject is diagnosed has having cancer.
  • the polypeptide is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof.
  • the invention provides a method for detecting cancer in a patient sample in which an antibody to a protein is used to react with proteins in the patient sample.
  • the antibody is specific for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof.
  • Antibodies can be generated routinely, e.g., to exposed regions of the polypeptides. For example, antibodies can be routinely generated to the extracellular domain of sVEGFR-2.
  • Another aspect of the present invention is a method for distinguishing between normal and disease states comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels of normal and disease tissues are analyzed, and a variation in the expression level of the gene and/or gene product is indicative of a disease state.
  • the gene or gene product is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
  • the invention pertains to a method of determining the phenotype of cells comprising detecting the differential expression, relative to normal cells, of at least one gene, wherein the gene is differentially expressed by at least a factor of two, at least a factor of five, at least a factor of twenty, or at least a factor of fifty.
  • the gene encodes PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
  • the invention pertains to a method of determining the phenotype of cells, comprising detecting the differential expression, relative to normal cells, of at least one polypeptide, wherein the protein is differentially expressed by at least a factor of two, at least a factor of five, at least a factor of twenty, an up to at least a factor of fifty.
  • the polypeptide is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof.
  • modulation of sKIT, CYTC or CK18M30 by Regorafenib exhibits a correlation between degree of change and clinical response.
  • baseline levels of IL16, SCF, HGF or TIMP2 are associated with clinical response to Regorafenib. Assays testing for these biomarkers may be advantageously employed to identify patients that would be likely to respond to Regorafenib. Such a selection of patients would be useful in the prescription of Regorafenib to patients.
  • the invention provides a test kit for identifying the presence of cancerous cells or tissues, comprising a probe/primer, for measuring a level of a nucleic acid in a sample of cells isolated from a patient.
  • the kit may further include instructions for using the kit, solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a nucleic acid susceptible to hybridization, solutions for lysing cells, or solutions for the purification of nucleic acids.
  • the probe/primer comprises a nucleotide sequence encoding a fragment of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
  • the invention provides a test kit for identifying the presence of cancer cells or tissues, comprising an antibody specific for a protein.
  • the kit further includes instructions for using the kit.
  • the kit may further include solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a polypeptide susceptible to the binding of an antibody, solutions for lysing cells, or solutions for the purification of polypeptides.
  • the antibody is specific for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
  • the invention provides a test kit for monitoring the efficacy of a compound or therapeutic, such as Regorafenib, in cancerous cells or tissues, comprising a probe/primer, for measuring a level of a nucleic acid in a sample of cells isolated from a patient.
  • the kit may further include instructions for using the kit, solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a nucleic acid susceptible to hybridization, solutions for lysing cells, or solutions for the purification of nucleic acids.
  • the probe/primer comprises the nucleotide sequence encoding PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
  • the invention provides a test kit for monitoring the efficacy of a compound or therapeutic in cancer cells or tissues, comprising an antibody specific for a protein.
  • the kit further includes instructions for using the kit.
  • the kit may further include solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a polypeptide susceptible to the binding of an antibody, solutions for lysing cells, or solutions for the purification of polypeptides.
  • the antibody is specific for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
  • Kits of this invention may advantageously comprise one or more (and often three or more) detectable reagents suitable for assaying the biomarkers discussed above.
  • detectable reagents may preferably be antibodies, as described above, either alone or in combination with reagents for the detection of proteins other than the biomarkers discussed above.
  • the kits may also include ancillary agents such as buffering agents and protein stabilizing agents, e.g., polysaccharides and the like.
  • Reference to diaryl urea multikinase inhibitors herein is intended to include the Regorafenib.
  • Reference to Regorafenib is intended to include a compound of formula I or a pharmaceutically acceptable salt, polymorph, solvate, hydrate, metabolite, prodrug or diastereoisomeric form thereof.
  • An "address" on an array refers to a location at which an element, for example, an oligonucleotide, is attached to the solid surface of the array.
  • agonist is meant to refer to an agent that mimics or up- regulates (e.g., potentiates or supplements) the bioactivity of a protein.
  • An agonist may be a wild-type protein or derivative thereof having at least one bioactivity of the wild-type protein.
  • An agonist may also be a compound that up-regulates expression of a gene or which increases at least one bioactivity of a protein.
  • An agonist can also be a compound which increases the interaction of a polypeptide with another molecule, for example, a target peptide or nucleic acid.
  • amplification relates to the production of additional copies of a nucleic acid sequence.
  • amplification may be carried out using polymerase chain reaction (PCR) technologies which are well known in the art. (see, e.g., Dieffenbach and Dveksler (1995) PCR Primer, A Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y.)
  • Antagonist is meant to refer to an agent that down-regulates (e.g., suppresses or inhibits) at least one bioactivity of a protein.
  • a Regorafenib is an example of such an antagonist.
  • An antagonist may be a compound which inhibits or decreases the interaction between a protein and another molecule, for example, a target peptide or enzyme substrate.
  • An antagonist may also be a compound that down-regulates expression of a gene or which reduces the amount of expressed protein present.
  • antibody is intended to include whole antibodies, for example, of any isotype (IgG, IgA, IgM, IgE, etc.), and includes fragments thereof which are also specifically reactive with a vertebrate (e.g., mammalian) protein.
  • Antibodies may be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies.
  • the term includes segments of proteolytically-cleaved or recombinantly-prepared portions of an antibody molecule that are capable of selectively reacting with a certain protein.
  • Non-limiting examples of such proteolytic and/or recombinant fragments include Fab, F(ab')2, Fab', Fv, and single chain antibodies (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker.
  • the scFv's may be covalently or non-covalently linked to form antibodies having two or more binding sites.
  • the subject invention includes polyclonal, monoclonal, or other purified preparations of antibodies and recombinant antibodies.
  • array or “matrix” refer to an arrangement of addressable locations or “addresses” on a device.
  • the locations can be arranged in two-dimensional arrays, three- dimensional arrays, or other matrix formats.
  • the number of locations may range from several to at least hundreds of thousands. Most importantly, each location represents a totally independent reaction site.
  • a "nucleic acid array” refers to an array containing nucleic acid probes, such as oligonucleotides or larger portions of genes.
  • the nucleic acid on the array is preferably single-stranded.
  • oligonucleotide arrays Arrays wherein the probes are oligonucleotides are referred to as “oligonucleotide arrays” or “oligonucleotide chips.”
  • a “microarray,” also referred to herein as a “biochip” or “biological chip,” is an array of regions having a density of discrete regions of at least about 100/cm 2 , and preferably at least about 1000/cm 2 .
  • the regions in a microarray have typical dimensions, for example, diameters, in the range of between about 10-250 ⁇ , and are separated from other regions in the array by about the same distance.
  • Bioactivity or “bioactivity” or “activity” or “biological function,” which are used interchangeably, herein mean an effector or antigenic function that is directly or indirectly performed by a polypeptide (whether in its native or denatured conformation), or by any subsequence thereof.
  • Biological activities include binding to polypeptides, binding to other proteins or molecules, activity as a DNA binding protein, as a transcription regulator, ability to bind damaged DNA, etc.
  • a bioactivity can be modulated by directly affecting the subject polypeptide.
  • a bioactivity can be altered by modulating the level of the polypeptide, such as by modulating expression of the corresponding gene.
  • biological sample refers to a sample obtained from an organism or from components (e.g., cells) of an organism.
  • the sample may be of any biological tissue or fluid.
  • the sample may be a sample which is derived from a patient.
  • samples include, but are not limited to, sputum, blood, blood cells (e.g., white cells), tissue or biopsy samples (e.g., tumor biopsy), urine, peritoneal fluid, and pleural fluid, or cells therefrom.
  • Biological samples may also include sections of tissues such as frozen sections taken for histological purposes.
  • Biomarker encompasses a broad range of intra- and extracellular events as well as whole-organism physiological changes.
  • Biomarkers may be represent essentially any aspect of cell function, for example, but not limited to, levels or rate of production of signaling molecules, transcription factors, metabolites, gene transcripts as well as post-translational modifications of proteins.
  • Biomarkers may include whole genome analysis of transcript levels or whole proteome analysis of protein levels and/or modifications.
  • a biomarker may also refer to a gene or gene product which is up- or down-regulated in a compound-treated, diseased cell of a subject having the disease compared to an untreated diseased cell. That is, the gene or gene product is sufficiently specific to the treated cell that it may be used, optionally with other genes or gene products, to identify, predict, or detect efficacy of a small molecule.
  • a biomarker is a gene or gene product that is characteristic of efficacy of a compound in a diseased cell or the response of that diseased cell to treatment by the compound.
  • a nucleotide sequence is "complementary" to another nucleotide sequence if each of the bases of the two sequences match, that is, are capable of forming Watson-Crick base pairs.
  • the term "complementary strand” is used herein interchangeably with the term “complement.”
  • the complement of a nucleic acid strand may be the complement of a coding strand or the complement of a non-coding strand.
  • Detection agents of genes refers to agents that can be used to specifically detect the gene or other biological molecules relating to it, for example, RNA transcribed from the gene or polypeptides encoded by the gene.
  • exemplary detection agents are nucleic acid probes, which hybridize to nucleic acids corresponding to the gene, and antibodies.
  • cancer includes, but is not limited to, solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid, and their distant metastases.
  • solid tumors such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid, and their distant metastases.
  • lymphomas, sarcomas, and leukemia include lymphomas, sarcomas, and leukemia.
  • breast cancer examples include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
  • cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
  • brain cancers include, but are not limited to, brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.
  • Tumors of the male reproductive organs include, but are not limited to, prostate and testicular cancer.
  • Tumors of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
  • Tumors of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.
  • Tumors of the urinary tract include, but are not limited to, bladder, penile, kidney, renal (e.g., renal cell carcinoma) pelvis, ureter, and urethral cancers.
  • Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma.
  • liver cancers include, but are not limited to, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
  • Skin cancers include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
  • Head-and-neck cancers include, but are not limited to, laryngeal / hypopharyngeal / nasopharyngeal / oropharyngeal cancer, and lip and oral cavity cancer.
  • Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
  • Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
  • Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
  • a diseased cell of cancer refers to a cell present in subjects having cancer. That is, a cell which is a modified form of a normal cell and is not present in a subject not having cancer, or a cell which is present in significantly higher or lower numbers in subjects having cancer relative to subjects not having cancer.
  • Equivalent is understood to include nucleotide sequences encoding functionally equivalent polypeptides.
  • Equivalent nucleotide sequences may include sequences that differ by one or more nucleotide substitutions, additions, or deletions, such as allelic variants.
  • expression profile which is used interchangeably herein with “gene expression profile” and “fingerprint” of a cell refers to a set of values representing mRNA levels of one or more genes in a cell.
  • An expression profile preferably comprises values representing expression levels of at least about 10 genes, preferably at least about 50, 100, 200 or more genes.
  • Expression profiles may also comprise an mRNA level of a gene which is expressed at similar levels in multiple cells and conditions (e.g., a housekeeping gene such as GAPDH).
  • an expression profile of a diseased cell of cancer refers to a set of values representing mRNA levels of 10 or more genes in a diseased cell.
  • the term "gene” refers to a nucleic acid sequence that comprises control and coding sequences necessary for the production of a polypeptide or precursor.
  • the polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence.
  • the gene may be derived in whole or in part from any source known to the art, including a plant, a fungus, an animal, a bacterial genome or episome, eukaryotic, nuclear or plasmid DNA, cDNA, viral DNA, or chemically synthesized DNA.
  • a gene may contain one or more modifications in either the coding or the untranslated regions which could affect the biological activity or the chemical structure of the expression product, the rate of expression, or the manner of expression control.
  • Such modifications include, but are not limited to, mutations, insertions, deletions, and substitutions of one or more nucleotides.
  • the gene may constitute an uninterrupted coding sequence or it may include one or more introns, bound by the appropriate splice junctions.
  • Hybridization refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.
  • two single- stranded nucleic acids "hybridize” when they form a double- stranded duplex.
  • the region of double-strandedness may include the full-length of one or both of the single- stranded nucleic acids, or all of one single- stranded nucleic acid and a subsequence of the other single- stranded nucleic acid, or the region of double-strandedness may include a subsequence of each nucleic acid.
  • Hybridization also includes the formation of duplexes which contain certain mismatches, provided that the two strands are still forming a double-stranded helix.
  • “Stringent hybridization conditions” refers to hybridization conditions resulting in essentially specific hybridization.
  • isolated refers to molecules separated from other DNAs or RNAs, respectively, that are present in the natural source of the macromolecule.
  • isolated as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
  • an "isolated nucleic acid” may include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state.
  • isolated is also used herein to refer to polypeptides which are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides.
  • label and “detectable label” refer to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, ligands (e.g., biotin or haptens), and the like.
  • fluorescer refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range.
  • the term “level of expression” refers to the measurable expression level of a given nucleic acid.
  • the level of expression of a nucleic acid is determined by methods well known in the art.
  • the term “differentially expressed” or “differential expression” refers to an increase or decrease in the measurable expression level of a given nucleic acid.
  • “differentially expressed” or “differential expression” means the difference in the level of expression of a nucleic acid is at least 1.4-fold or more in two samples used for comparison, both of which are compared to the same normal standard sample.
  • “Differentially expressed” or “differential expression” also means a 1.4-fold, or more, up to and including 2-fold, 5 -fold, 10-fold, 20-fold, 50-fold or more difference in the level of expression of a nucleic acid in two samples used for comparison.
  • a nucleic acid is also said to be “differentially expressed” in two samples if one of the two samples contains no detectable expression of a given nucleic acid, provided that the detectably expressed nucleic acid is expressed at +/- at least 1.4 fold.
  • Differential expression of a nucleic acid sequence is "inhibited" the difference in the level of expression of the nucleic acid in two or more samples used for comparison is altered such that it is no longer at least a 1.4 fold difference.
  • Absolute quantification of the level of expression of a nucleic acid may be accomplished by including a known concentration(s) of one or more control nucleic acid species, generating a standard curve based on the amount of the control nucleic acid and extrapolating the expression level of the "unknown" nucleic acid species from the hybridization intensities of the unknown with respect to the standard curve.
  • nucleic acid refers to polynucleotides such as deoxyribonucleic acid (DNA) and, where appropriate, ribonucleic acid (RNA).
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • Chromosomes, cDNAs, mRNAs, rRNAs, and ESTs are representative examples of molecules that may be referred to as nucleic acids.
  • oligonucleotide refers to a nucleic acid molecule comprising, for example, from about 10 to about 1000 nucleotides. Oligonucleotides for use in the present invention are preferably from about 15 to about 150 nucleotides, more preferably from about 150 to about 1000 in length.
  • the oligonucleotide may be a naturally occurring oligonucleotide or a synthetic oligonucleotide. Oligonucleotides may be prepared by the phosphoramidite method (Beaucage and Carruthers, Tetrahedron Lett. 22: 1859-62, 1981), or by the triester method (Matteucci, et al., J. Am. Chem. Soc. 103:3185, 1981), or by other chemical methods known in the art.
  • patient or "subject” as used herein includes mammals (e.g., humans and animals).
  • a nucleic acid or other molecule attached to an array is referred to as a "probe” or “capture probe.”
  • probe or capture probe
  • a gene-probe set may consist of, for example, about 2 to about 20 probes, preferably from about 2 to about 10 probes, and most preferably about 5 probes.
  • the "profile" of a cell's biological state refers to the levels of various constituents of a cell that are known to change in response to drug treatments and other perturbations of the biological state of the cell.
  • Constituents of a cell include, for example, levels of RNA, levels of protein abundances, or protein activity levels.
  • protein is used interchangeably herein with the terms “peptide” and “polypeptide.”
  • An expression profile in one cell is "similar" to an expression profile in another cell when the level of expression of the genes in the two profiles are sufficiently similar that the similarity is indicative of a common characteristic, for example, the same type of cell. Accordingly, the expression profiles of a first cell and a second cell are similar when at least 75% of the genes that are expressed in the first cell are expressed in the second cell at a level that is within a factor of two relative to the first cell.
  • Small molecule refers to a composition with a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids, or other organic or inorganic molecules. Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures, often fungal, bacterial, or algal extracts, which can be screened with any of the assays of the invention to identify compounds that modulate a bioactivity.
  • hybridization of a probe to a target site of a template nucleic acid refers to hybridization of the probe predominantly to the target, such that the hybridization signal can be clearly interpreted.
  • such conditions resulting in specific hybridization vary depending on the length of the region of homology, the GC content of the region, and the melting temperature ("Tm") of the hybrid.
  • Tm melting temperature
  • hybridization conditions may vary in salt content, acidity, and temperature of the hybridization solution and the washes.
  • a "variant" of polypeptide refers to a polypeptide having an amino acid sequence in which one or more amino acid residues is altered.
  • the variant may have "conservative” changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine).
  • a variant may also have "nonconservative” changes (e.g., replacement of glycine with tryptophan).
  • Analogous minor variations may include amino acid deletions or insertions, or both.
  • Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be identified using computer programs well known in the art, for example, LASERGENE software (DNASTAR).
  • variants when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to that of a particular gene or the coding sequence thereof. This definition may also include, for example, "allelic,” “splice,” “species,” or “polymorphic” variants.
  • a splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing.
  • the corresponding polypeptide may possess additional functional domains or an absence of domains.
  • Species variants are polynucleotide sequences that vary from one species to another.
  • polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species.
  • Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.
  • SNPs single nucleotide polymorphisms
  • An aspect of the invention is directed to the identification of agents, such as Regorafenib, as to their capability of modulating the differentiation and proliferation of cells characterized by aberrant proliferation. More specifically, the invention relates to methods of screening candidate compounds, such as Regorafenib, for their ability to regulate the differential expression of nucleic acid sequences. That is, if a nucleic acid sequence is overexpressed in cancer cells, then the candidate compounds (e.g., Regorafenib) are tested/screened for their ability to decrease expression, and if a nucleic acid sequence is underexpressed in cancer cells, then a test compound (e.g., Regorafenib) is tested/screened for its ability to increase expression.
  • candidate compounds e.g., Regorafenib
  • a test compound e.g., Regorafenib
  • the invention relates to screening assays to identify whether test compounds, such as Regorafenib, can modulate the activity of one or more polypeptides which are encoded by the differentially expressed sequences described herein.
  • test compounds such as Regorafenib
  • the invention provides assays for determining whether compounds, such as Regorafenib, modulate the expression of marker nucleic acids and/or alter the bioactivity of the encoded polypeptide. Screening for modulation of differential expression
  • Drug screening is performed by adding a test compound (e.g., Regorafenib and derivatives thereof) to a sample of cells, and monitoring the effect. A parallel sample which does not receive the test compound is also monitored as a control.
  • the treated and untreated cells are then compared by any suitable phenotypic criteria, including but not limited to microscopic analysis, viability testing, ability to replicate, histological examination, the level of a particular RNA or polypeptide associated with the cells, the level of enzymatic activity expressed by the cells or cell lysates, and the ability of the cells to interact with other cells or compounds. Differences between treated and untreated cells indicates effects attributable to the test compound.
  • Desirable effects of a test compound include an effect on any phenotype that was conferred by the cancer-associated marker nucleic acid sequence. Examples include a test compound that limits the overabundance of mRNA, limits production of the encoded protein, or limits the functional effect of the protein. The effect of the test compound would be apparent when comparing results between treated and untreated cells.
  • the invention thus, also encompasses methods of screening for agents (e.g., Regorafenib and derivatives thereof) which inhibit or enhance the expression of the nucleic acid markers in vitro, comprising exposing a cell or tissue in which the marker nucleic acid mRNA (e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF ) is detectable in cultured cells to an agent in order to determine whether the agent is capable of inhibiting or enhancing production of the mRNA; and determining the level of mRNA in the exposed cells or tissue, wherein a decrease in the level of the mRNA after exposure of the cell line to the agent is indicative of inhibition of the marker nucleic acid mRNA production and an increase in mRNA levels is indicative of enhancement of maker mRNA production.
  • agents e.g., Regora
  • the screening method may include in vitro screening of a cell or tissue in which marker protein is detectable in cultured cells to an agent suspected of inhibiting or enhancing production of the marker protein; and determining the level of the marker protein in the cells or tissue, wherein a decrease in the level of marker protein after exposure of the cells or tissue to the agent is indicative of inhibition of marker protein production and an increase on the level of marker protein is indicative of enhancement of marker protein production.
  • the invention also encompasses in vivo methods of screening for agents which inhibit or enhance expression of the marker nucleic acids, comprising exposing a subject having tumor cells in which marker mRNA or protein is detectable to an agent suspected of inhibiting or enhancing production of marker mRNA or protein; and determining the level of marker mRNA or protein in tumor cells of the exposed mammal.
  • a decrease in the level of marker mRNA or protein after exposure of the subject to the agent is indicative of inhibition of marker nucleic acid expression and an increase in the level of marker mRNA or protein is indicative of enhancement of marker nucleic acid expression.
  • the invention provides a method comprising incubating a cell expressing the marker nucleic acids with a test compound and measuring the mRNA or protein level.
  • the invention further provides a method for quantitatively determining the level of expression of the marker nucleic acids in a cell population, and a method for determining whether an agent is capable of increasing or decreasing the level of expression of the marker nucleic acids in a cell population.
  • the method for determining whether an agent is capable of increasing or decreasing the level of expression of the marker nucleic acids in a cell population comprises the steps of (a) preparing cell extracts from control and agent-treated cell populations, (b) isolating the marker polypeptides from the cell extracts, and (c) quantifying (e.g., in parallel) the amount of an immunocomplex formed between the marker polypeptide and an antibody specific to said polypeptide.
  • the marker polypeptides of this invention may also be quantified by assaying for its bioactivity.
  • Agents that induce an increase in the marker nucleic acid expression may be identified by their ability to increase the amount of immunocomplex formed in the treated cell as compared with the amount of the immunocomplex formed in the control cell.
  • agents that decrease expression of the marker nucleic acid may be identified by their ability to decrease the amount of the immunocomplex formed in the treated cell extract as compared to the control cell.
  • the present invention provides a method for identifying a nucleotide sequence which is differentially regulated in a subject with cancer, comprising: hybridizing a nucleic acid sample corresponding to RNA obtained from the subject to a nucleic acid sample comprising one or more nucleic acid molecules of known identity; and measuring the hybridization of the nucleic acid sample to the one or more nucleic acid molecules of known identity, wherein a two-fold difference in the hybridization of the nucleic acid sample to the one or more nucleic acid molecules of known identity relative to a nucleic acid sample obtained from a subject without cancer is indicative of the differential expression of the nucleotide sequence in a subject with cancer.
  • the present invention provides a method for identifying nucleic acid sequences which are differentially regulated in a subject with cancer comprising isolating messenger RNA from a subject, generating cRNA from the mRNA sample, hybridizing the cRNA to a microarray comprising a plurality of nucleic acid molecules stably associated with discrete locations on the array, and identifying patterns of hybridization of the cRNA to the array.
  • a nucleic acid molecule which hybridizes to a given location on the array is said to be differentially regulated if the hybridization signal is at least two-fold higher or lower than the hybridization signal at the same location on an identical array hybridized with a nucleic acid sample obtained from a subject that does not have cancer.
  • Determining gene expression levels may be accomplished utilizing microarrays. Generally, the following steps may be involved: (a) obtaining an mRNA sample from a subject and preparing labeled nucleic acids therefrom (the "target nucleic acids” or “targets”); (b) contacting the target nucleic acids with an array under conditions sufficient for the target nucleic acids to bind to the corresponding probes on the array, for example, by hybridization or specific binding; (c) optional removal of unbound targets from the array; (d) detecting the bound targets, and (e) analyzing the results, for example, using computer based analysis methods.
  • “nucleic acid probes” or “probes” are nucleic acids attached to the array
  • target nucleic acids are nucleic acids that are hybridized to the array.
  • Nucleic acid specimens may be obtained from a subject to be tested using either “invasive” or “non-invasive” sampling means.
  • a sampling means is said to be “invasive” if it involves the collection of nucleic acids from within the skin or organs of an animal (including murine, human, ovine, equine, bovine, porcine, canine, or feline animal).
  • invasive methods include, for example, blood collection, semen collection, needle biopsy, pleural aspiration, umbilical cord biopsy. Examples of such methods are discussed by Kim, et al., (J. Virol. 66:3879-3882, 1992); Biswas, et al., (Ann. NY Acad. Sci. 590:582-583, 1990); and Biswas, et al., (J. Clin. Microbiol. 29:2228-2233, 1991).
  • a “non-invasive” sampling means is one in which the nucleic acid molecules are recovered from an internal or external surface of the animal.
  • Examples of such "non-invasive” sampling means include, for example, “swabbing,” collection of tears, saliva, urine, fecal material, sweat or perspiration, hair.
  • RNA is isolated from the cells.
  • a sample of peripheral blood leukocytes (PBLs) cells is obtained from the subject. It is also possible to obtain a cell sample from a subject, and then to enrich the sample for a desired cell type. For example, cells may be isolated from other cells using a variety of techniques, such as isolation with an antibody binding to an epitope on the cell surface of the desired cell type.
  • the desired cells are in a solid tissue
  • particular cells may be dissected, for example, by microdissection or by laser capture microdissection (LCM) (see, e.g., Bonner, et al., Science 278: 1481, 1997; Emmert-Buck, et al., Science 274:998, 1996; Fend, et al., Am. J. Path. 154:61, 1999; and Murakami, et al., Kidney Int. 58: 1346, 2000).
  • LCM laser capture microdissection
  • RNA may be extracted from tissue or cell samples by a variety of methods, for example, guanidium thiocyanate lysis followed by CsCl centrifugation (Chirgwin, et al., Biochemistry 18:5294-5299, 1979).
  • RNA from single cells may be obtained as described in methods for preparing cDNA libraries from single cells (see, e.g., Dulac, Curr. Top. Dev. Biol. 36:245, 1998; Jena, et al., J. Immunol. Methods 190: 199, 1996).
  • RNA sample can be further enriched for a particular species.
  • poly(A)+ RNA may be isolated from an RNA sample.
  • the RNA population may be enriched for sequences of interest by primer-specific cDNA synthesis, or multiple rounds of linear amplification based on cDNA synthesis and template- directed in vitro transcription (see, e.g., Wang, et al., Proc. Natl. Acad. Sci. USA 86:9717, 1989; Dulac, et al., supra; Jena, et al., supra).
  • RNA may be further amplified by a variety of amplification methods including, for example, PCR; ligase chain reaction (LCR) (see, e.g., Wu and Wallace, Genomics 4:560, 1989; Landegren, et al., Science 241 : 1077, 1988); self-sustained sequence replication (SSR) (see, e.g., Guatelli, et al., Proc. Natl. Acad. Sci. USA 87: 1874, 1990); nucleic acid based sequence amplification (NASBA) and transcription amplification (see, e.g., Kwoh, et al., Proc. Natl.
  • LCR ligase chain reaction
  • SSR self-sustained sequence replication
  • NASBA nucleic acid based sequence amplification
  • transcription amplification see, e.g., Kwoh, et al., Proc. Natl.
  • PCR technology Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, N.Y., N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila, et al., Nucleic Acids Res. 19:4967, 1991; Eckert, et al., PCR Methods and Applications 1: 17, 1991 ; PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. No.
  • RNA amplification and cDNA synthesis may also be conducted in cells in situ (see, e.g., Eberwine, et al. Proc. Natl. Acad. Sci. USA 89:3010, 1992).
  • the nucleic acid molecules may be labeled to permit detection of hybridization of the nucleic acid molecules to a microarray. That is, the probe may comprise a member of a signal producing system and thus, is detectable, either directly or through combined action with one or more additional members of a signal producing system.
  • the nucleic acids may be labeled with a fluorescently labeled dNTP (see, e.g., Kricka, 1992, Nonisotopic DNA Probe Techniques, Academic Press San Diego, Calif.), biotinylated dNTPs or rNTP followed by addition of labeled streptavidin, chemiluminescent labels, or isotopes.
  • Hybridization may be also be determined, for example, by plasmon resonance (see, e.g., Thiel, et al. Anal. Chem. 69:4948, 1997).
  • a plurality (e.g., 2, 3, 4, 5, or more) of sets of target nucleic acids are labeled and used in one hybridization reaction ("multiplex" analysis).
  • one set of nucleic acids may correspond to RNA from one cell and another set of nucleic acids may correspond to RNA from another cell.
  • the plurality of sets of nucleic acids may be labeled with different labels, for example, different fluorescent labels (e.g., fluorescein and rhodamine) which have distinct emission spectra so that they can be distinguished.
  • the sets may then be mixed and hybridized simultaneously to one microarray (see, e.g., Shena, et al., Science 270:467-470, 1995).
  • Microarrays for use according to the invention include one or more probes of genes characteristic of small molecule efficacy.
  • the microarray comprises probes corresponding to one or more of genes selected from the group consisting of genes which are up-regulated in cancer and genes which are down-regulated in cancer.
  • the microarray may comprise probes corresponding to at least 10, preferably at least 20, at least 50, at least 100 or at least 1000 genes characteristic of small molecule efficacy.
  • a microarray may contain from 2 to 20 probes corresponding to one gene and preferably about 5 to 10.
  • the probes may correspond to the full-length RNA sequence or complement thereof of genes characteristic of small molecule efficacy, or the probe may correspond to a portion thereof, which portion is of sufficient length to permit specific hybridization.
  • Such probes may comprise from about 50 nucleotides to about 100, 200, 500, or 1000 nucleotides or more than 1000 nucleotides.
  • microarrays may contain oligonucleotide probes, consisting of about 10 to 50 nucleotides, preferably about 15 to 30 nucleotides and more preferably about 20-25 nucleotides.
  • the probes are preferably single-stranded and will have sufficient complementarity to its target to provide for the desired level of sequence specific hybridization.
  • the arrays used in the present invention will have a site density of greater than 100 different probes per cm 2 .
  • the arrays will have a site density of greater than 500/cm 2 , more preferably greater than about 1000/cm 2 , and most preferably, greater than about 10,000/cm 2 .
  • the arrays will have more than 100 different probes on a single substrate, more preferably greater than about 1000 different probes, still more preferably, greater than about 10,000 different probes and most preferably, greater than 100,000 different probes on a single substrate.
  • Arrays preferably include control and reference nucleic acids.
  • Control nucleic acids include, for example, prokaryotic genes such as bioB, bioC and bioD, ere from PI bacteriophage or polyA controls, such as dap, lys, phe, thr, and trp.
  • Reference nucleic acids allow the normalization of results from one experiment to another and the comparison of multiple experiments on a quantitative level.
  • exemplary reference nucleic acids include housekeeping genes of known expression levels, for example, GAPDH, hexokinase, and actin.
  • an array of oligonucleotides may be synthesized on a solid support.
  • Exemplary solid supports include glass, plastics, polymers, metals, metalloids, ceramics, organics, etc.
  • chip masking technologies and photoprotective chemistry it is possible to generate ordered arrays of nucleic acid probes.
  • These arrays which are known, for example, as "DNA chips” or very large scale immobilized polymer arrays (“VLSIPSTM" arrays), may include millions of defined probe regions on a substrate having an area of about 1 cm 2 to several cm 2 , thereby incorporating from a few to millions of probes (see, e.g., U.S. Patent No. 5,631,734).
  • labeled nucleic acids may be contacted with the array under conditions sufficient for binding between the target nucleic acid and the probe on the array.
  • the hybridization conditions may be selected to provide for the desired level of hybridization specificity; that is, conditions sufficient for hybridization to occur between the labeled nucleic acids and probes on the microarray.
  • Hybridization may be carried out in conditions permitting essentially specific hybridization.
  • the length and GC content of the nucleic acid will determine the thermal melting point and thus, the hybridization conditions necessary for obtaining specific hybridization of the probe to the target nucleic acid. These factors are well known to a person of skill in the art, and may also be tested in assays.
  • An extensive guide to nucleic acid hybridization may be found in Tijssen, et al. (Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 24: Hybridization With Nucleic Acid Probes, P. Tijssen, ed. Elsevier, N.Y., (1993)).
  • the methods described above result in the production of hybridization patterns of labeled target nucleic acids on the array surface.
  • the resultant hybridization patterns of labeled nucleic acids may be visualized or detected in a variety of ways, with the particular manner of detection selected based on the particular label of the target nucleic acid.
  • Representative detection means include scintillation counting, autoradiography, fluorescence measurement, colorimetric measurement, light emission measurement, light scattering, and the like.
  • One such method of detection utilizes an array scanner that is commercially available (Affymetrix, Santa Clara, CA), for example, the 417TM Arrayer, the 418TM Array Scanner, or the Agilent GeneArrayTM Scanner.
  • This scanner is controlled from a system computer with an interface and easy-to-use software tools. The output may be directly imported into or directly read by a variety of software applications.
  • Preferred scanning devices are described in, for example, U.S. Patent Nos. 5,143,854 and 5,424,186.
  • the fluorescence emissions at each site of a transcript array may be, preferably, detected by scanning confocal laser microscopy.
  • a laser may be used that allows simultaneous specimen illumination at wavelengths specific to the two fluorophores and emissions from the two fluorophores may be analyzed simultaneously (see, e.g., Shalon, et al., Genome Res. 6:639-645, 1996).
  • the arrays may be scanned with a laser fluorescent scanner with a computer controlled X-Y stage and a microscope objective. Fluorescence laser scanning devices are described in Shalon, et al., supra.
  • Various algorithms are available for analyzing gene expression data, for example, the type of comparisons to perform.
  • a preferred embodiment for identifying such groups of genes involves clustering algorithms (for reviews of clustering algorithms, see, e.g., Fukunaga, 1990, Statistical Pattern Recognition, 2nd Ed., Academic Press, San Diego; Everitt, 1974, Cluster Analysis, London: Heinemann Educ. Books; Hartigan, 1975, Clustering Algorithms, New York: Wiley; Sneath and Sokal, 1973, Numerical Taxonomy, Freeman; Anderberg, 1973, Cluster Analysis for Applications, Academic Press: New York).
  • Expression patterns may be used to derive a panel of biomarkers that can be used to predict the efficacy of drug treatment in the patients.
  • the biomarkers may consist of gene expression levels from microarray experiments on RNA isolated from biological samples, RNA isolated from frozen samples of tumor biopsies, or mass spectrometry-derived protein masses in the serum.
  • a typical procedure for developing a panel of biomarkers is as follows. The data (gene expression levels or mass spectra) are collected for each patient prior to treatment. As the study progresses, the patients are classified according to their response to the drug treatment; either as efficacious or non-efficacious.
  • the protein and/or gene expression data may be analyzed by a number of techniques known in the art. Many of the techniques are derived from traditional statistics as well from the field of machine learning. These techniques serve two purposes:
  • plasma (1 ⁇ ) may be applied to a hydrophobic SELDI-target, washed extensively in water, and analyzed by the SELDI-Tof mass spectrometer. This may be repeated on 100 or more patient samples.
  • the protein profiles resulting from the intensities of some 16,000 m/z values in each sample would be statistically analyzed in order to identify sets of specific m/z values that are predictive of drug efficacy.
  • Identical experiments using other SELDI-targets, such as ion-exchange or IMAC surfaces could also be conducted. These will capture different subsets of the proteins present in plasma.
  • the plasma may be denatured and prefractionated prior to application onto the SELDI target.
  • the present invention provides methods for determining whether a subject is at risk for developing a disease or condition characterized by unwanted cell proliferation by detecting biomarkers (e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF), that is, nucleic acids and/or polypeptide markers for cancer.
  • biomarkers e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF
  • human tissue samples may be screened for the presence and/or absence of biomarkers identified herein.
  • samples could consist of needle biopsy cores, surgical resection samples, lymph node tissue, or serum.
  • these methods include obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich tumor cells to about 80% of the total cell population.
  • nucleic acids extracted from these samples may be amplified using techniques well known in the art. The levels of selected markers detected would be compared with statistically valid groups of metastatic, non-metastatic malignant, benign, or normal tissue samples.
  • the diagnostic method comprises determining whether a subject has an abnormal mRNA and/or protein level of the biomarkers (e.g., PLGF, CALX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF), such as by Northern blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, immunoprecipitation, Western blot hybridization, or immunohistochemistry.
  • the biomarkers e.g., PLGF, CALX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF
  • cells may be obtained from a subject and the levels of the biomarkers, protein, or mRNA level, are determined and compared to the level of these markers in a healthy subject.
  • An abnormal level of the biomarker polypeptide or mRNA levels is likely to be indicative of cancer.
  • the method comprises using a nucleic acid probe to determine the presence of cancerous cells in a tissue from a patient. Specifically, the method comprises:
  • nucleic acid probe comprising a nucleotide sequence at least 10 nucleotides in length, preferably at least 15 nucleotides, more preferably, 25 nucleotides, and most preferably at least 40 nucleotides, and up to all or nearly all of the coding sequence which is complementary to a portion of the coding sequence of a nucleic acid sequence and is differentially expressed in tumors cells;
  • RNA of each of said first and second tissue samples e.g., in a Northern blot or in situ hybridization assay
  • the method comprises in situ hybridization with a probe derived from a given marker nucleic acid sequence (e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF).
  • a given marker nucleic acid sequence e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
  • the method comprises contacting the labeled hybridization probe with a sample of a given type of tissue potentially containing cancerous or pre-cancerous cells as well as normal cells, and determining whether the probe labels some cells of the given tissue type to a degree significantly different (e.g., by at least a factor of two, or at least a factor of five, or at least a factor of twenty, or at least a factor of fifty) than the degree to which it labels other cells of the same tissue type.
  • a degree significantly different e.g., by at least a factor of two, or at least a factor of five, or at least a factor of twenty, or at least a factor of fifty
  • Also within the invention is a method of determining the phenotype of a test cell from a given human tissue, for example, whether the cell is (a) normal, or (b) cancerous or precancerous, by contacting the mRNA of a test cell with a nucleic acid probe at least 12 nucleotides in length, preferably at least 15 nucleotides, more preferably at least 25 nucleotides, and most preferably at least 40 nucleotides, and up to all or nearly all of a sequence which is complementary to a portion of the coding sequence of a nucleic acid sequence, and which is differentially expressed in tumor cells as compared to normal cells of the given tissue type; and determining the approximate amount of hybridization of the probe to the mRNA, an amount of hybridization either more or less than that seen with the mRNA of a normal cell of that tissue type being indicative that the test cell is cancerous or precancerous.
  • the above diagnostic assays may be carried out using antibodies to detect the protein product encoded by the marker nucleic acid sequence (e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF).
  • the marker nucleic acid sequence e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
  • the assay would include contacting the proteins of the test cell with an antibody specific for the gene product of a nucleic acid, the marker nucleic acid being one which is expressed at a given control level in normal cells of the same tissue type as the test cell, and determining the approximate amount of immunocomplex formation by the antibody and the proteins of the test cell, wherein a statistically significant difference in the amount of the immunocomplex formed with the proteins of a test cell as compared to a normal cell of the same tissue type is an indication that the test cell is cancerous or pre-cancerous.
  • the antibody is specific for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF, especially its extracellular domain.
  • Another such method includes the steps of: providing an antibody specific for the gene product of a marker nucleic acid sequence, the gene product being present in cancerous tissue of a given tissue type at a level more or less than the level of the gene product in noncancerous tissue of the same tissue type; obtaining from a patient a first sample of tissue of the given tissue type, which sample potentially includes cancerous cells; providing a second sample of tissue of the same tissue type (which may be from the same patient or from a normal control, e.g.
  • this second sample containing normal cells and essentially no cancerous cells; contacting the antibody with protein (which may be partially purified, in lysed but unfractionated cells, or in situ) of the first and second samples under conditions permitting immunocomplex formation between the antibody and the marker nucleic acid sequence product present in the samples; and comparing (a) the amount of immunocomplex formation in the first sample, with (b) the amount of immunocomplex formation in the second sample, wherein a statistically significant difference in the amount of immunocomplex formation in the first sample less as compared to the amount of immunocomplex formation in the second sample is indicative of the presence of cancerous cells in the first sample of tissue.
  • protein which may be partially purified, in lysed but unfractionated cells, or in situ
  • the subject invention further provides a method of determining whether a cell sample obtained from a subject possesses an abnormal amount of marker polypeptide which comprises (a) obtaining a cell sample from the subject, (b) quantitatively determining the amount of the marker polypeptide in the sample so obtained, and (c) comparing the amount of the marker polypeptide so determined with a known standard, so as to thereby determine whether the cell sample obtained from the subject possesses an abnormal amount of the marker polypeptide.
  • marker polypeptides may be detected by immunohistochemical assays, dot-blot assays, ELISA, and the like.
  • Immunoassays are commonly used to quantitate the levels of proteins in cell samples, and many other immunoassay techniques are known in the art.
  • the invention is not limited to a particular assay procedure, and therefore, is intended to include both homogeneous and heterogeneous procedures.
  • Exemplary immunoassays which may be conducted according to the invention include fluorescence polarization immunoassay (FPIA), fluorescence immunoassay (FIA), enzyme immunoassay (EIA), nephelometric inhibition immunoassay (NIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA).
  • An indicator moiety, or label group may be attached to the subject antibodies and is selected so as to meet the needs of various uses of the method which are often dictated by the availability of assay equipment and compatible immunoassay procedures. Conditions suitable for the formation of antibody- antigen complexes are well known in the art. General techniques to be used in performing the various immunoassays noted above are known to those of ordinary skill in the art. See generally E. Maggio, Enzyme-Immunoassay, (1980) (CRC Press, Inc., Boca Raton, Fla.); see also, e.g., U.S. Pat. No.
  • Monoclonal antibodies of the invention may be used in a "two-site” or “sandwich” assay, with a single cell line serving as a source for both the labeled monoclonal antibody and the bound monoclonal antibody.
  • assays are described in U.S. Pat. No. 4,376,110.
  • concentration of detectable reagent should be sufficient such that the binding of mutant BCR-ABL is detectable compared to background. It will be understood that more than one antibody may be used in the practice of the above-described methods.
  • the level of the encoded product, or alternatively the level of the polypeptide, in a biological fluid (e.g., blood or urine) of a patient may be determined as a way of monitoring the level of expression of the marker nucleic acid sequence in cells of that patient.
  • a biological fluid e.g., blood or urine
  • Such a method would include the steps of obtaining a sample of a biological fluid from the patient, contacting the sample (or proteins from the sample) with an antibody specific for an encoded marker polypeptide, and determining the amount of immune complex formation by the antibody, with the amount of immune complex formation being indicative of the level of the marker encoded product in the sample. This determination is particularly instructive when compared to the amount of immune complex formation by the same antibody in a control sample taken from a normal individual or in one or more samples previously or subsequently obtained from the same person.
  • the method may be used to determine the amount of marker polypeptide present in a cell, which in turn may be correlated with progression of a hyperproliferative disorder.
  • the level of the marker polypeptide may be used predictively to evaluate whether a sample of cells contains cells which are, or are predisposed towards becoming, transformed cells.
  • the subject method may be used to assess the phenotype of cells which are known to be transformed, the phenotyping results being useful in planning a particular therapeutic regimen. For example, very high levels of the marker polypeptide in sample cells is a powerful diagnostic and prognostic marker for a cancer. The observation of marker polypeptide levels may be utilized in decisions regarding, for example, the use of more aggressive therapies.
  • one aspect of the present invention relates to diagnostic assays for determining, in the context of cells isolated from a patient, if the level of a marker polypeptide is significantly reduced in the sample cells.
  • the term "significantly reduced” refers to a cell phenotype wherein the cell possesses a reduced cellular amount of the marker polypeptide relative to a normal cell of similar tissue origin.
  • a cell may have less than about 50%, 25%, 10%, or 5% of the marker polypeptide compared to that of a normal control cell.
  • the assay evaluates the level of marker polypeptide in the test cells, and, preferably, compares the measured level with marker polypeptide detected in at least one control cell, for example, a normal cell and/or a transformed cell of known phenotype.
  • the number of cells with a particular marker polypeptide phenotype may then be correlated with patient prognosis.
  • the marker polypeptide phenotype of a lesion is determined as a percentage of cells in a biopsy which are found to have abnormally high/low levels of the marker polypeptide. Such expression may be detected by immunohistochemical assays, dot-blot assays, ELISA, and the like.
  • immunohistochemical staining may be used to determine the number of cells having the marker polypeptide phenotype.
  • a multiblock of tissue may be taken from the biopsy or other tissue sample and subjected to proteolytic hydrolysis, employing such agents as protease K or pepsin.
  • proteolytic hydrolysis employing such agents as protease K or pepsin.
  • tissue samples are fixed by treatment with a reagent such as formalin, glutaraldehyde, methanol, or the like.
  • a reagent such as formalin, glutaraldehyde, methanol, or the like.
  • the samples are then incubated with an antibody, preferably a monoclonal antibody, with binding specificity for the marker polypeptides.
  • This antibody may be conjugated to a label for subsequent detection of binding.
  • Samples are incubated for a time sufficient for formation of the immunocomplexes. Binding of the antibody is then detected by virtue of a label conjugated to this antibody.
  • a second labeled antibody may be employed, for example, which is specific for the isotype of the anti-marker polypeptide antibody.
  • labels which may be employed include radionuclides, fluorescers, chemiluminescers, enzymes, and the like.
  • the substrate for the enzyme may be added to the samples to provide a colored or fluorescent product.
  • suitable enzymes for use in conjugates include horseradish peroxidase, alkaline phosphatase, malate dehydrogenase, and the like. Where not commercially available, such antibody-enzyme conjugates are readily produced by techniques known to those skilled in the art.
  • the assay is performed as a dot blot assay.
  • the dot blot assay finds particular application where tissue samples are employed as it allows determination of the average amount of the marker polypeptide associated with a single cell by correlating the amount of marker polypeptide in a cell-free extract produced from a predetermined number of cells.
  • the invention provides for a battery of tests utilizing a number of probes of the invention, in order to improve the reliability and/or accuracy of the diagnostic test.
  • the present invention also provides a method wherein nucleic acid probes are immobilized on a DNA chip in an organized array.
  • Oligonucleotides may be bound to a solid support by a variety of processes, including lithography.
  • a chip may hold up to 250,000 oligonucleotides.
  • nucleic acid probes comprise a nucleotide sequence at least about 12 nucleotides in length, preferably at least about 15 nucleotides, more preferably at least about 25 nucleotides, and most preferably at least about 40 nucleotides, and up to all or nearly all of a sequence which is complementary to a portion of the coding sequence of a marker nucleic acid sequence and is differentially expressed in tumor cells.
  • the present invention provides significant advantages over the available tests for various cancers, because it increases the reliability of the test by providing an array of nucleic acid markers on a single chip.
  • the method includes obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich tumor cells to about 80% of the total cell population.
  • the DNA or RNA is then extracted, amplified, and analyzed with a DNA chip to determine the presence of absence of the marker nucleic acid sequences.
  • the nucleic acid probes are spotted onto a substrate in a two- dimensional matrix or array.
  • Samples of nucleic acids may be labeled and then hybridized to the probes.
  • Double-stranded nucleic acids, comprising the labeled sample nucleic acids bound to probe nucleic acids, may be detected once the unbound portion of the sample is washed away.
  • the probe nucleic acids may be spotted on substrates including glass, nitrocellulose, etc.
  • the probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions.
  • the sample nucleic acids can be labeled using radioactive labels, fluorophores, chromophores, etc.
  • arrays may be used to examine differential expression of genes and may be used to determine gene function.
  • arrays of nucleic acid sequences may be used to determine if any of the nucleic acid sequences are differentially expressed between normal cells and cancer cells. Increased expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, may indicate a cancer-specific protein.
  • nucleic acid molecules may be used to generate microarrays on a solid surface (e.g., a membrane) such that the arrayed nucleic acid molecules may be used to determine if any of the nucleic acids are differentially expressed between normal cells or tissue and cancerous cells or tissue.
  • the nucleic acid molecules of the invention may be cDNA or may be used to generate cDNA molecules to be subsequently amplified by PCR and spotted on nylon membranes. The membranes may then be reacted with radiolabeled target nucleic acid molecules obtained from equivalent samples of cancerous and normal tissue or cells.
  • the invention contemplates using a panel of antibodies which are generated against the marker polypeptides of this invention.
  • the antibodies are generated against PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
  • a panel of antibodies may be used as a reliable diagnostic probe for cancer.
  • the assay of the present invention comprises contacting a biopsy sample containing cells, for example, lung cells, with a panel of antibodies to one or more of the encoded products to determine the presence or absence of the marker polypeptides.
  • the diagnostic methods of the subject invention may also be employed as follow-up to treatment, for example, quantitation of the level of marker polypeptides may be indicative of the effectiveness of current or previously employed cancer therapies as well as the effect of these therapies upon patient prognosis.
  • marker nucleic acids or marker polypeptides may be utilized as part of a diagnostic panel for initial detection, follow-up screening, detection of reoccurrence, and post-treatment monitoring for chemotherapy or surgical treatment.
  • the present invention makes available diagnostic assays and reagents for detecting gain and/or loss of marker polypeptides from a cell in order to aid in the diagnosis and phenotyping of proliferative disorders arising from, for example, tumorigenic transformation of cells.
  • the diagnostic assays described above may be adapted to be used as prognostic assays, as well. Such an application takes advantage of the sensitivity of the assays of the invention to events which take place at characteristic stages in the progression of a tumor. For example, a given marker gene may be up- or down-regulated at a very early stage, perhaps before the cell is irreversibly committed to developing into a malignancy, while another marker gene may be characteristically up- or down-regulated only at a much later stage.
  • Such a method could involve the steps of contacting the mRNA of a test cell with a nucleic acid probe derived from a given marker nucleic acid which is expressed at different characteristic levels in cancerous or precancerous cells at different stages of tumor progression, and determining the approximate amount of hybridization of the probe to the mRNA of the cell, such amount being an indication of the level of expression of the gene in the cell, and thus an indication of the stage of tumor progression of the cell; alternatively, the assay may be carried out with an antibody specific for the gene product of the given marker nucleic acid, contacted with the proteins of the test cell.
  • a battery of such tests will disclose not only the existence and location of a tumor, but also will allow the clinician to select the mode of treatment most appropriate for the tumor, and to predict the likelihood of success of that treatment.
  • the methods of the invention may also be used to follow the clinical course of a tumor.
  • the assay of the invention may be applied to a tissue sample from a patient; following treatment of the patient for the cancer, another tissue sample is taken and the test repeated. Successful treatment will result in either removal of all cells which demonstrate differential expression characteristic of the cancerous or precancerous cells, or a substantial increase in expression of the gene in those cells, perhaps approaching or even surpassing normal levels.
  • a biomarker associated with the anti-cancer agent may be analyzed in a biological sample (e.g., tumor sample, plasma) before, during, and following treatment.
  • a biological sample e.g., tumor sample, plasma
  • the expression of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF, polypeptide may be detected in plasma.
  • changes in the baseline plasma concentration of these polypeptides may be monitored in patients with cancer.
  • increased levels of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD or ANG2 and decreased levels of SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF can be associated with Regorafenib efficacy.
  • VEGF-A VEGF-D PLGF, ANG2
  • HGF pro-angiogenic factors
  • bFGF pro-angiogenic factors
  • Soluble forms of receptors that may be targeted by Regorafenib generally decreased in response to Regorafenib (sVEGFR2, sTIE- l,s-c-Kit).
  • Metalloproteinase inhibitors TIMP2 and TIMP4 decreased in response to Regorafenib.
  • Regorafenib increased the levels of P1GF in 96% of the patients and decreased the levels of sVEGFR2 and TIMP2 in 100% of patients.
  • polypeptide levels may also be monitored by quantitative immunohistochemistry using paraffin-embedded tumor biopsies.
  • Another approach to monitor treatment is an evaluation of serum proteomic spectra.
  • plasma samples may be subjected to mass spectroscopy (e.g., surface-enhanced laser desorption and ionization) and a proteomic spectra may be generated for each patient.
  • mass spectroscopy e.g., surface-enhanced laser desorption and ionization
  • a set of spectra, derived from analysis of plasma from patients before and during treatment may be analyzed by an iterative searching algorithm, which can identify a proteomic pattern that completely discriminates the treated samples from the untreated samples. The resulting pattern may then be used to predict the clinical benefit following treatment.
  • RNA isolated from cells derived from whole blood from patients before and during treatment may be used to generate blood cell gene expression profiles utilizing Affymetrix GeneChip technology and algorithms. These gene expression profiles may then predict the clinical benefit from treatment with a particular anti-cancer agent.
  • Figure 1 is six graphs showing the Regorafenib-mediated changes in PLGF
  • Figure 2 is three graphs showing the predictive value of raf mediated changes in plasma protein levels.
  • Figure 3 is five graphs showing the predicative value of base line plasma protein levels
  • Patients and methods Patients selected for treatment with Regorafenib and analysis for biomarkers had previously untreated metastatic or unresectable clear cell RCC. These patients received oral Regorafenib (160 mg/day) in repeating cycles of 3 weeks on / 1 week off until disease progression or until patients met the criteria for removal from study. Primary efficacy endpoint was overall objective response rate. Secondary efficacy endpoints included overall survival, progression-free survival (PFS), time to progression, duration of response, duration of stable disease, disease control rate and clinical benefit rate. Safety was assessed by analysis of adverse events (AEs) and changes in laboratory, vital signs, and electrocardiogram measurements.
  • AEs adverse events
  • Plasma protein biomarkers were quantified using multiplex bead immunoassays. Plasma was obtained at baseline and after 15 days of daily Regorafenib treatment from 29 patients (pts) with previously untreated unresectable or metastatic RCC enrolled in a Phase II trial that demonstrated Regorafenib clinical activity. Biomarkers examined included soluble forms of receptors inhibited by Regorafenib, for example, soluble VEGF receptor-2 (sVEGFR2), soluble KIT (sKIT) and their ligands, for example, VEGF, SCF.
  • sVEGF receptor-2 soluble VEGF receptor-2
  • KIT soluble KIT
  • HGF hypoxia
  • CAFX hypoxia
  • apoptosis for example, CK18M30, CYTC
  • tumor invasion for example, TIMP2
  • Results indicate that a subset of biomarkers was altered by exposure to Regorafenib.
  • PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2 levels were increased.
  • the levels of sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, SCF were decreased.
  • the most consistent, robust changes were in PLGF (increase in 27/28 pts (96%); median fold change of +3.3; p ⁇ 0.0001) and sVEGFR2 (decrease in 28/28 pts(100%); median fold change of -1.6; p ⁇ 0.0001) and TIMP2 (decrease in 28/28 pts(100%)).
  • circulating levels of several receptors that may be targeted by Regorafenib were decreased.
  • sVEGFR2, sKIT, sTIEl Several members of the VEGF family of ligands (PLGF, VEGFA, VEGFD) were increased.
  • Potential biomarkers that did not change included ANG1, GCSF, HGF, IL16, MCSF, sMCSFR, OPN, PDGFAA, AB and BB, SDFloc, sTIE2, TIMP1 and 3, VEGFC, sVEGFRl and sVEGFR3.
  • Figure 2 shows the changes in Regorafenib-mediated plasma levels of CK18M30 in patients grouped based on maximum tumor shrinkage and best response, and changes in s-c- kit based on maximum tumor shrinkage.
  • the degree change(s) in sKIT, CYTC or CK18M30 levels is/are correlated with clinical response to Regorafenib.
  • baseline levels of IL16, SCF, HGF or TIMP2 are associated with clinical response to Regorafenib. Assays testing for these biomarkers may be advantageously employed to identify patients that would be likely to respond to Regorafenib.
  • Tissue specimens can optionally be analyzed for VHL gene mutation status (only for patients consenting to genetic analysis) by DNA sequencing, and phospho-ERK (pERK) levels by immunohistochemistry (IHC).
  • mRNA can be isolated from blood and analyzed by microarrays for gene expression profiles that correlate with patient outcome. Additionally or alternatively, a mass spectrometry-based approach can be used to assess plasma for a protein signature, and urine can optionally be analyzed by ⁇ -NMR for patterns of small molecules that correlate with patient outcome.
  • Pre- and post-treatment plasma samples are analyzed by ELISA for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF, and changes in these molecules related to Regorafenib treatment are investigated.
  • the PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF levels in patients can be examined to identify correlations with clinical outcome (time to death (TTD) and progression-free survival (PFS) using a Cox regression analysis.
  • TTD time to death
  • PFS progression-free survival
  • Baseline levels of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF are first determined and changes in the baseline levels are determined after treatment, preferably at about week 18 of treatment. The effects observed were adjusted for age, gender, ECOG status or Motzer score. These adjustments were minimal.

Abstract

The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the response to treatment with an anticancer agent.

Description

BIOMARKERS FOR A MULTIKINASE INHIBITOR
CROSS REFERENCE TO RELATED APPLICATIONS
[001] This application claims priority to provisional application 61/346,433, filed May 19, 2010.
[002] The invention relates generally to cancer and biomarkers, and more particularly to identification of clinically useful serum (plasma treatment) and/or tumor biomarkers and expression signatures that can be used for prognostication and guidance for the treatment of cancer patients, such as patients with renal cell carcinoma (RCC), with a multikinase inhibitor, such as, for example, Regorafenib (solely or in combination with other agents).
BACKGROUND OF THE INVENTION
[003] Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults and is one of the most lethal tumors. Where the tumor is confined to the renal parenchyma, the 5- year survival rate is 60-70%, but this is lowered considerably where metastases have spread. As such, there is a strong need for advancement in prognosis, early detection, and treatment of RCC.
[004] Diaryl urea compounds such as Regorafenib, 4{4-[3-(4-chloro-3- trifluoromethylphenyl)-ureido] -3 -fluorophenoxy } -pyridine-2-carboxylic acid methylamide, and its derivatives as described for example in US 20050038080, are potent anti-cancer and anti-angiogenic agents that possess various activities, including inhibitory activity on the VEGFR, PDGFR, raf, p38, and/or flt-3 kinase signaling molecules. These diaryl urea compounds have been previously characterized as having various activities, including for inhibiting the Raf/MEK ERK pathway, raf kinase, p38 kinase, VEGFR kinase, PDGFR kinase. These activities and their use in treating various diseases and conditions are disclosed in, e.g., WO 2005/009961. Regorafenib is an investigational anti-cancer drug with a distinct profile targeting angiogenic (VEGFR, TIE-2), stromal (PDGFR) and oncogenic (RAF, RET and c-KIT) receptor tyrosine kinases. Two major metabolites of Regorafenib, M2 and M5, demonstrated antitumor activity that was comparable to the parent drug. (Zopf et al., Regorafenib (BAY 73-4506): identification of clinically relevant metabolites and their preclinical pharmacology. Poster 1666 presented at the 101st AACR Annual Meeting, Washington DC, USA, 17-21 April, 2010.) In Phase I studies, Regorafenib was well tolerated and displayed substantial antitumor efficacy in multiple tumor types, including RCC (Frost et al., Phase I Study of BAY 73-4506, an Inhibitor of Oncogenic and Angiogenic Kinases, in Patients With Advanced Solid Tumors: Final Results of a Dose-Escalation Study. Poster 2558 presented at the ASCO, 2008), colorectal carcinoma (Strumberg et al. Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC). J Clin Oncol (Meeting Abstracts) 2009; 27 (15S): 161s, abs 3560) and non-small-cell lung cancer (Kies et al, Phase I study of Regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2010; 28 (15 suppl), abs 7585).
[005] It is recognized that despite having a cancer in which the targeted receptors are over- expressed or over-activated, certain subsets of patients may be resistant to a kinase-targeted therapeutic such as Regorafenib. There is an important and pressing need to recognize resistance or responsiveness to therapeutics such as Regorafenib in order to timely select the most efficacious treatment. It would be highly desirable to have biomarkers or a combination of biomarkers that are not only useful in the identification of RCC but also allow characterization of RCC, for example, those that are draggable with Regorafenib.
[006] US Patent 7,833736 discloses ten protein biomarkers: Heat Shock Protein-27 (HSP- 27), Cortactin, Cdc25C (or phospho-Cdc25C (Ser216 or Thr48)), phospho-MAPKAPK-2 (Thr334), phospho-Cyclin E (Thr62), Stathmin, phospho-ATF2 (Thr69 or Thr71), phospho- Histone H3 (Thr3), phospho-EIF-4B (Ser422), and phospho-Rpbl (Ser2 or Ser5), that are said to predictive of cancer resistance or responsiveness to targeted inhibitors of certain Receptor Tyrosine Kinases (RTKs). Also disclosed are methods for identifying the resistance or responsiveness of certain cancers, tumors, and patients to these inhibitors, including renal cell carcinoma, with these protein biomarkers. Kits for identifying the resistance or responsiveness of certain cancers, tumors, and patients to these inhibitors are disclosed which comprise detectable reagents for three or more of the 10 biomarker proteins. It is said the kits can be employed on biopsy samples, fine needle aspirates, or biological fluids such as serum, blood plasma, or bone marrow, and may comprise whole cells or a cell lysate, whether or not isolated. SUMMARY OF THE INVENTION
[007] The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF as biomarkers for efficacy of treatment with diaryl urea multikinase inhibitors such as Regorafenib. As described in more detail in the example below, it has been found that sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF decreased in subjects treated with Regorafenib, while PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, or ANG2 levels increased. Thus, these markers can be used to determine the efficacy of Regorafenib treatment.
[008] In addition, it is an objective of the invention to provide methods and reagents for the prediction, diagnosis, prognosis, and therapy of cancer, such as RCC.
[009] Another embodiment of the present invention is a method for screening the effects of a drug on a tissue or cell sample comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels in the tissue or cell sample are analyzed before and after exposure to the drug, and a variation in the expression level of the gene and/or gene product is indicative of a drug effect or provides a patient diagnosis or predicts a patient's response to the treatment. In a further embodiment, the drug is a Regorafenib. In another embodiment, the gene or gene product is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF, and soluble forms thereof.
[010] The invention further provides a method for identifying a compound useful for the treatment of cancer comprising administering to a subject with cancer a test compound, and measuring the activity of the polypeptide, wherein a change in the activity of the polypeptide is indicative of the test compound being useful for the treatment of cancer. In a further embodiment, the polypeptide is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof (e.g., detection of shed VEGFR2), and in another embodiment, the compound is a Regorafenib.
[011] The invention, thus, provides methods which may be used to identify compounds which may act, for example, as regulators or modulators such as agonists and antagonists, partial agonists, inverse agonists, activators, co-activators, and inhibitors. Accordingly, the invention provides reagents and methods for regulating the expression of a polynucleotide or a polypeptide associated with cancer. Reagents that modulate the expression, stability, or amount of a polynucleotide or the activity of the polypeptide may be a protein, a peptide, a peptidomimetic, a nucleic acid, a nucleic acid analogue (e.g., peptide nucleic acid, locked nucleic acid), or a small molecule.
[012] The present invention also provides a method for providing a patient diagnosis comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels of normal and patient samples are analyzed, and a variation in the expression level of the gene and/or gene product in the patient sample is diagnostic of a disease. The patient samples include, but are not limited to, blood, amniotic fluid, plasma, semen, bone marrow, and tissue biopsy. In a further embodiment, the gene or gene product is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof.
[013] The present invention still further provides a method of diagnosing cancer in a subject comprising measuring the activity of the polypeptide in a subject suspected of having cancer, wherein if there is a difference in the activity of the polypeptide, relative to the activity of the polypeptide in a subject not suspected of having cancer, then the subject is diagnosed has having cancer. In a further embodiment, the polypeptide is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof.
[014] In another embodiment, the invention provides a method for detecting cancer in a patient sample in which an antibody to a protein is used to react with proteins in the patient sample. In a still further embodiment, the antibody is specific for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof. Antibodies can be generated routinely, e.g., to exposed regions of the polypeptides. For example, antibodies can be routinely generated to the extracellular domain of sVEGFR-2.
[015] Another aspect of the present invention is a method for distinguishing between normal and disease states comprising the step of analyzing the level of expression of one or more genes and/or gene products, wherein the gene expression and/or gene product levels of normal and disease tissues are analyzed, and a variation in the expression level of the gene and/or gene product is indicative of a disease state. In a further aspect, the gene or gene product is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
[016] In another embodiment, the invention pertains to a method of determining the phenotype of cells comprising detecting the differential expression, relative to normal cells, of at least one gene, wherein the gene is differentially expressed by at least a factor of two, at least a factor of five, at least a factor of twenty, or at least a factor of fifty. In a further embodiment, the gene encodes PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
[017] In yet another embodiment, the invention pertains to a method of determining the phenotype of cells, comprising detecting the differential expression, relative to normal cells, of at least one polypeptide, wherein the protein is differentially expressed by at least a factor of two, at least a factor of five, at least a factor of twenty, an up to at least a factor of fifty. In a further embodiment, the polypeptide is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF and soluble forms thereof.
[018] In one preferred embodiment of the method of this invention, modulation of sKIT, CYTC or CK18M30 by Regorafenib exhibits a correlation between degree of change and clinical response.
[019] In another preferred embodiment of the method of this invention, baseline levels of IL16, SCF, HGF or TIMP2 are associated with clinical response to Regorafenib. Assays testing for these biomarkers may be advantageously employed to identify patients that would be likely to respond to Regorafenib. Such a selection of patients would be useful in the prescription of Regorafenib to patients.
[020] In another embodiment, the invention provides a test kit for identifying the presence of cancerous cells or tissues, comprising a probe/primer, for measuring a level of a nucleic acid in a sample of cells isolated from a patient. In certain embodiments, the kit may further include instructions for using the kit, solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a nucleic acid susceptible to hybridization, solutions for lysing cells, or solutions for the purification of nucleic acids. In a further embodiment, the probe/primer comprises a nucleotide sequence encoding a fragment of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
[021] In one embodiment, the invention provides a test kit for identifying the presence of cancer cells or tissues, comprising an antibody specific for a protein. In certain embodiments, the kit further includes instructions for using the kit. In certain embodiments, the kit may further include solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a polypeptide susceptible to the binding of an antibody, solutions for lysing cells, or solutions for the purification of polypeptides. In a still further embodiment, the antibody is specific for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
[022] In another embodiment, the invention provides a test kit for monitoring the efficacy of a compound or therapeutic, such as Regorafenib, in cancerous cells or tissues, comprising a probe/primer, for measuring a level of a nucleic acid in a sample of cells isolated from a patient. In certain embodiments, the kit may further include instructions for using the kit, solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a nucleic acid susceptible to hybridization, solutions for lysing cells, or solutions for the purification of nucleic acids. In a further embodiment, the probe/primer comprises the nucleotide sequence encoding PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
[023] In one embodiment, the invention provides a test kit for monitoring the efficacy of a compound or therapeutic in cancer cells or tissues, comprising an antibody specific for a protein. In certain embodiments, the kit further includes instructions for using the kit. In certain embodiments, the kit may further include solutions for suspending or fixing the cells, detectable tags or labels, solutions for rendering a polypeptide susceptible to the binding of an antibody, solutions for lysing cells, or solutions for the purification of polypeptides. In a still further embodiment, the antibody is specific for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
[024] Kits of this invention may advantageously comprise one or more (and often three or more) detectable reagents suitable for assaying the biomarkers discussed above. Such detectable reagents may preferably be antibodies, as described above, either alone or in combination with reagents for the detection of proteins other than the biomarkers discussed above. The kits may also include ancillary agents such as buffering agents and protein stabilizing agents, e.g., polysaccharides and the like.
DETAILED DESCRIPTION OF THE INVENTION
[025] It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
[026] Reference to diaryl urea multikinase inhibitors herein is intended to include the Regorafenib. Reference to Regorafenib is intended to include a compound of formula I or a pharmaceutically acceptable salt, polymorph, solvate, hydrate, metabolite, prodrug or diastereoisomeric form thereof.
Figure imgf000009_0001
[027] It must be noted that as used herein and in the appended claims, the singular forms "a," "and," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a gene" is a reference to one or more genes and includes equivalents thereof known to those skilled in the art, and so forth.
[028] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.
[029] All publications and patents mentioned herein are hereby incorporated herein by reference for the purpose of describing and disclosing, for example, the constructs and methodologies that are described in the publications which might be used in connection with the presently described invention. The publications discussed above and throughout the text are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.
Definitions
[030] For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided below.
[031] An "address" on an array (e.g., a microarray) refers to a location at which an element, for example, an oligonucleotide, is attached to the solid surface of the array.
[032] The term "agonist," as used herein, is meant to refer to an agent that mimics or up- regulates (e.g., potentiates or supplements) the bioactivity of a protein. An agonist may be a wild-type protein or derivative thereof having at least one bioactivity of the wild-type protein. An agonist may also be a compound that up-regulates expression of a gene or which increases at least one bioactivity of a protein. An agonist can also be a compound which increases the interaction of a polypeptide with another molecule, for example, a target peptide or nucleic acid.
[033] "Amplification," as used herein, relates to the production of additional copies of a nucleic acid sequence. For example, amplification may be carried out using polymerase chain reaction (PCR) technologies which are well known in the art. (see, e.g., Dieffenbach and Dveksler (1995) PCR Primer, A Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y.)
[034] "Antagonist," as used herein, is meant to refer to an agent that down-regulates (e.g., suppresses or inhibits) at least one bioactivity of a protein. For example, a Regorafenib is an example of such an antagonist. An antagonist may be a compound which inhibits or decreases the interaction between a protein and another molecule, for example, a target peptide or enzyme substrate. An antagonist may also be a compound that down-regulates expression of a gene or which reduces the amount of expressed protein present.
[035] The term "antibody," as used herein, is intended to include whole antibodies, for example, of any isotype (IgG, IgA, IgM, IgE, etc.), and includes fragments thereof which are also specifically reactive with a vertebrate (e.g., mammalian) protein. Antibodies may be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. Thus, the term includes segments of proteolytically-cleaved or recombinantly-prepared portions of an antibody molecule that are capable of selectively reacting with a certain protein. Non-limiting examples of such proteolytic and/or recombinant fragments include Fab, F(ab')2, Fab', Fv, and single chain antibodies (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker. The scFv's may be covalently or non-covalently linked to form antibodies having two or more binding sites. The subject invention includes polyclonal, monoclonal, or other purified preparations of antibodies and recombinant antibodies.
[036] The terms "array" or "matrix" refer to an arrangement of addressable locations or "addresses" on a device. The locations can be arranged in two-dimensional arrays, three- dimensional arrays, or other matrix formats. The number of locations may range from several to at least hundreds of thousands. Most importantly, each location represents a totally independent reaction site. A "nucleic acid array" refers to an array containing nucleic acid probes, such as oligonucleotides or larger portions of genes. The nucleic acid on the array is preferably single-stranded. Arrays wherein the probes are oligonucleotides are referred to as "oligonucleotide arrays" or "oligonucleotide chips." A "microarray," also referred to herein as a "biochip" or "biological chip," is an array of regions having a density of discrete regions of at least about 100/cm2, and preferably at least about 1000/cm2. The regions in a microarray have typical dimensions, for example, diameters, in the range of between about 10-250 μιη, and are separated from other regions in the array by about the same distance.
[037] "Biological activity" or "bioactivity" or "activity" or "biological function," which are used interchangeably, herein mean an effector or antigenic function that is directly or indirectly performed by a polypeptide (whether in its native or denatured conformation), or by any subsequence thereof. Biological activities include binding to polypeptides, binding to other proteins or molecules, activity as a DNA binding protein, as a transcription regulator, ability to bind damaged DNA, etc. A bioactivity can be modulated by directly affecting the subject polypeptide. Alternatively, a bioactivity can be altered by modulating the level of the polypeptide, such as by modulating expression of the corresponding gene.
[038] The term "biological sample," as used herein, refers to a sample obtained from an organism or from components (e.g., cells) of an organism. The sample may be of any biological tissue or fluid. The sample may be a sample which is derived from a patient. Such samples include, but are not limited to, sputum, blood, blood cells (e.g., white cells), tissue or biopsy samples (e.g., tumor biopsy), urine, peritoneal fluid, and pleural fluid, or cells therefrom. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes.
[039] The term "biomarker" or "marker" encompasses a broad range of intra- and extracellular events as well as whole-organism physiological changes. Biomarkers may be represent essentially any aspect of cell function, for example, but not limited to, levels or rate of production of signaling molecules, transcription factors, metabolites, gene transcripts as well as post-translational modifications of proteins. Biomarkers may include whole genome analysis of transcript levels or whole proteome analysis of protein levels and/or modifications.
[040] A biomarker may also refer to a gene or gene product which is up- or down-regulated in a compound-treated, diseased cell of a subject having the disease compared to an untreated diseased cell. That is, the gene or gene product is sufficiently specific to the treated cell that it may be used, optionally with other genes or gene products, to identify, predict, or detect efficacy of a small molecule. Thus, a biomarker is a gene or gene product that is characteristic of efficacy of a compound in a diseased cell or the response of that diseased cell to treatment by the compound.
[041] A nucleotide sequence is "complementary" to another nucleotide sequence if each of the bases of the two sequences match, that is, are capable of forming Watson-Crick base pairs. The term "complementary strand" is used herein interchangeably with the term "complement." The complement of a nucleic acid strand may be the complement of a coding strand or the complement of a non-coding strand.
[042] "Detection agents of genes" refers to agents that can be used to specifically detect the gene or other biological molecules relating to it, for example, RNA transcribed from the gene or polypeptides encoded by the gene. Exemplary detection agents are nucleic acid probes, which hybridize to nucleic acids corresponding to the gene, and antibodies.
[043] The term "cancer" includes, but is not limited to, solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid, and their distant metastases. The term also includes lymphomas, sarcomas, and leukemia.
[044] Examples of breast cancer include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ. [045] Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
[046] Examples of brain cancers include, but are not limited to, brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.
[047] Tumors of the male reproductive organs include, but are not limited to, prostate and testicular cancer. Tumors of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
[048] Tumors of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.
[049] Tumors of the urinary tract include, but are not limited to, bladder, penile, kidney, renal (e.g., renal cell carcinoma) pelvis, ureter, and urethral cancers.
Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma.
Examples of liver cancers include, but are not limited to, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
Skin cancers include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
Head-and-neck cancers include, but are not limited to, laryngeal / hypopharyngeal / nasopharyngeal / oropharyngeal cancer, and lip and oral cavity cancer.
Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia. [050] "A diseased cell of cancer" refers to a cell present in subjects having cancer. That is, a cell which is a modified form of a normal cell and is not present in a subject not having cancer, or a cell which is present in significantly higher or lower numbers in subjects having cancer relative to subjects not having cancer.
[051] The term "equivalent" is understood to include nucleotide sequences encoding functionally equivalent polypeptides. Equivalent nucleotide sequences may include sequences that differ by one or more nucleotide substitutions, additions, or deletions, such as allelic variants.
[052] The term "expression profile," which is used interchangeably herein with "gene expression profile" and "fingerprint" of a cell refers to a set of values representing mRNA levels of one or more genes in a cell. An expression profile preferably comprises values representing expression levels of at least about 10 genes, preferably at least about 50, 100, 200 or more genes. Expression profiles may also comprise an mRNA level of a gene which is expressed at similar levels in multiple cells and conditions (e.g., a housekeeping gene such as GAPDH). For example, an expression profile of a diseased cell of cancer refers to a set of values representing mRNA levels of 10 or more genes in a diseased cell.
[053] The term "gene" refers to a nucleic acid sequence that comprises control and coding sequences necessary for the production of a polypeptide or precursor. The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence. The gene may be derived in whole or in part from any source known to the art, including a plant, a fungus, an animal, a bacterial genome or episome, eukaryotic, nuclear or plasmid DNA, cDNA, viral DNA, or chemically synthesized DNA. A gene may contain one or more modifications in either the coding or the untranslated regions which could affect the biological activity or the chemical structure of the expression product, the rate of expression, or the manner of expression control. Such modifications include, but are not limited to, mutations, insertions, deletions, and substitutions of one or more nucleotides. The gene may constitute an uninterrupted coding sequence or it may include one or more introns, bound by the appropriate splice junctions.
[054] "Hybridization" refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing. For example, two single- stranded nucleic acids "hybridize" when they form a double- stranded duplex. The region of double-strandedness may include the full-length of one or both of the single- stranded nucleic acids, or all of one single- stranded nucleic acid and a subsequence of the other single- stranded nucleic acid, or the region of double-strandedness may include a subsequence of each nucleic acid. Hybridization also includes the formation of duplexes which contain certain mismatches, provided that the two strands are still forming a double-stranded helix. "Stringent hybridization conditions" refers to hybridization conditions resulting in essentially specific hybridization.
[055] The term "isolated," as used herein, with respect to nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs or RNAs, respectively, that are present in the natural source of the macromolecule. The term "isolated" as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Moreover, an "isolated nucleic acid" may include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state. The term "isolated" is also used herein to refer to polypeptides which are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides.
[056] As used herein, the terms "label" and "detectable label" refer to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, ligands (e.g., biotin or haptens), and the like. The term "fluorescer" refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range. Particular examples of labels which may be used in the present invention include fluorescein, rhodamine, dansyl, umbelliferone, Texas red, luminol, NADPH, alpha - beta -galactosidase, and horseradish peroxidase.
[057] As used herein, the term "level of expression" refers to the measurable expression level of a given nucleic acid. The level of expression of a nucleic acid is determined by methods well known in the art. The term "differentially expressed" or "differential expression" refers to an increase or decrease in the measurable expression level of a given nucleic acid. As used herein, "differentially expressed" or "differential expression" means the difference in the level of expression of a nucleic acid is at least 1.4-fold or more in two samples used for comparison, both of which are compared to the same normal standard sample. "Differentially expressed" or "differential expression" according to the invention also means a 1.4-fold, or more, up to and including 2-fold, 5 -fold, 10-fold, 20-fold, 50-fold or more difference in the level of expression of a nucleic acid in two samples used for comparison. A nucleic acid is also said to be "differentially expressed" in two samples if one of the two samples contains no detectable expression of a given nucleic acid, provided that the detectably expressed nucleic acid is expressed at +/- at least 1.4 fold. Differential expression of a nucleic acid sequence is "inhibited" the difference in the level of expression of the nucleic acid in two or more samples used for comparison is altered such that it is no longer at least a 1.4 fold difference. Absolute quantification of the level of expression of a nucleic acid may be accomplished by including a known concentration(s) of one or more control nucleic acid species, generating a standard curve based on the amount of the control nucleic acid and extrapolating the expression level of the "unknown" nucleic acid species from the hybridization intensities of the unknown with respect to the standard curve.
[058] As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA) and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs and, as applicable to the embodiment being described, single- stranded (sense or antisense) and double-stranded polynucleotides. Chromosomes, cDNAs, mRNAs, rRNAs, and ESTs are representative examples of molecules that may be referred to as nucleic acids.
[059] The term "oligonucleotide" as used herein refers to a nucleic acid molecule comprising, for example, from about 10 to about 1000 nucleotides. Oligonucleotides for use in the present invention are preferably from about 15 to about 150 nucleotides, more preferably from about 150 to about 1000 in length. The oligonucleotide may be a naturally occurring oligonucleotide or a synthetic oligonucleotide. Oligonucleotides may be prepared by the phosphoramidite method (Beaucage and Carruthers, Tetrahedron Lett. 22: 1859-62, 1981), or by the triester method (Matteucci, et al., J. Am. Chem. Soc. 103:3185, 1981), or by other chemical methods known in the art.
[060] The term "patient" or "subject" as used herein includes mammals (e.g., humans and animals).
[061] As used herein, a nucleic acid or other molecule attached to an array is referred to as a "probe" or "capture probe." When an array contains several probes corresponding to one gene, these probes are referred to as a "gene-probe set." A gene-probe set may consist of, for example, about 2 to about 20 probes, preferably from about 2 to about 10 probes, and most preferably about 5 probes.
[062] The "profile" of a cell's biological state refers to the levels of various constituents of a cell that are known to change in response to drug treatments and other perturbations of the biological state of the cell. Constituents of a cell include, for example, levels of RNA, levels of protein abundances, or protein activity levels.
[063] The term "protein" is used interchangeably herein with the terms "peptide" and "polypeptide."
[064] An expression profile in one cell is "similar" to an expression profile in another cell when the level of expression of the genes in the two profiles are sufficiently similar that the similarity is indicative of a common characteristic, for example, the same type of cell. Accordingly, the expression profiles of a first cell and a second cell are similar when at least 75% of the genes that are expressed in the first cell are expressed in the second cell at a level that is within a factor of two relative to the first cell.
[065] "Small molecule," as used herein, refers to a composition with a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids, or other organic or inorganic molecules. Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures, often fungal, bacterial, or algal extracts, which can be screened with any of the assays of the invention to identify compounds that modulate a bioactivity.
[066] The term "specific hybridization" of a probe to a target site of a template nucleic acid refers to hybridization of the probe predominantly to the target, such that the hybridization signal can be clearly interpreted. As further described herein, such conditions resulting in specific hybridization vary depending on the length of the region of homology, the GC content of the region, and the melting temperature ("Tm") of the hybrid. Thus, hybridization conditions may vary in salt content, acidity, and temperature of the hybridization solution and the washes.
[067] A "variant" of polypeptide refers to a polypeptide having an amino acid sequence in which one or more amino acid residues is altered. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). A variant may also have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be identified using computer programs well known in the art, for example, LASERGENE software (DNASTAR).
[068] The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to that of a particular gene or the coding sequence thereof. This definition may also include, for example, "allelic," "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.
[069] An aspect of the invention is directed to the identification of agents, such as Regorafenib, as to their capability of modulating the differentiation and proliferation of cells characterized by aberrant proliferation. More specifically, the invention relates to methods of screening candidate compounds, such as Regorafenib, for their ability to regulate the differential expression of nucleic acid sequences. That is, if a nucleic acid sequence is overexpressed in cancer cells, then the candidate compounds (e.g., Regorafenib) are tested/screened for their ability to decrease expression, and if a nucleic acid sequence is underexpressed in cancer cells, then a test compound (e.g., Regorafenib) is tested/screened for its ability to increase expression. In addition, the invention relates to screening assays to identify whether test compounds, such as Regorafenib, can modulate the activity of one or more polypeptides which are encoded by the differentially expressed sequences described herein. In this regard, the invention provides assays for determining whether compounds, such as Regorafenib, modulate the expression of marker nucleic acids and/or alter the bioactivity of the encoded polypeptide. Screening for modulation of differential expression
[070] Drug screening is performed by adding a test compound (e.g., Regorafenib and derivatives thereof) to a sample of cells, and monitoring the effect. A parallel sample which does not receive the test compound is also monitored as a control. The treated and untreated cells are then compared by any suitable phenotypic criteria, including but not limited to microscopic analysis, viability testing, ability to replicate, histological examination, the level of a particular RNA or polypeptide associated with the cells, the level of enzymatic activity expressed by the cells or cell lysates, and the ability of the cells to interact with other cells or compounds. Differences between treated and untreated cells indicates effects attributable to the test compound.
[071] Desirable effects of a test compound include an effect on any phenotype that was conferred by the cancer-associated marker nucleic acid sequence. Examples include a test compound that limits the overabundance of mRNA, limits production of the encoded protein, or limits the functional effect of the protein. The effect of the test compound would be apparent when comparing results between treated and untreated cells.
[072] The invention thus, also encompasses methods of screening for agents (e.g., Regorafenib and derivatives thereof) which inhibit or enhance the expression of the nucleic acid markers in vitro, comprising exposing a cell or tissue in which the marker nucleic acid mRNA (e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF ) is detectable in cultured cells to an agent in order to determine whether the agent is capable of inhibiting or enhancing production of the mRNA; and determining the level of mRNA in the exposed cells or tissue, wherein a decrease in the level of the mRNA after exposure of the cell line to the agent is indicative of inhibition of the marker nucleic acid mRNA production and an increase in mRNA levels is indicative of enhancement of maker mRNA production.
[073] Alternatively, the screening method may include in vitro screening of a cell or tissue in which marker protein is detectable in cultured cells to an agent suspected of inhibiting or enhancing production of the marker protein; and determining the level of the marker protein in the cells or tissue, wherein a decrease in the level of marker protein after exposure of the cells or tissue to the agent is indicative of inhibition of marker protein production and an increase on the level of marker protein is indicative of enhancement of marker protein production. [074] The invention also encompasses in vivo methods of screening for agents which inhibit or enhance expression of the marker nucleic acids, comprising exposing a subject having tumor cells in which marker mRNA or protein is detectable to an agent suspected of inhibiting or enhancing production of marker mRNA or protein; and determining the level of marker mRNA or protein in tumor cells of the exposed mammal. A decrease in the level of marker mRNA or protein after exposure of the subject to the agent is indicative of inhibition of marker nucleic acid expression and an increase in the level of marker mRNA or protein is indicative of enhancement of marker nucleic acid expression.
[075] Accordingly, the invention provides a method comprising incubating a cell expressing the marker nucleic acids with a test compound and measuring the mRNA or protein level. The invention further provides a method for quantitatively determining the level of expression of the marker nucleic acids in a cell population, and a method for determining whether an agent is capable of increasing or decreasing the level of expression of the marker nucleic acids in a cell population. The method for determining whether an agent is capable of increasing or decreasing the level of expression of the marker nucleic acids in a cell population comprises the steps of (a) preparing cell extracts from control and agent-treated cell populations, (b) isolating the marker polypeptides from the cell extracts, and (c) quantifying (e.g., in parallel) the amount of an immunocomplex formed between the marker polypeptide and an antibody specific to said polypeptide. The marker polypeptides of this invention may also be quantified by assaying for its bioactivity. Agents that induce an increase in the marker nucleic acid expression may be identified by their ability to increase the amount of immunocomplex formed in the treated cell as compared with the amount of the immunocomplex formed in the control cell. In a similar manner, agents that decrease expression of the marker nucleic acid may be identified by their ability to decrease the amount of the immunocomplex formed in the treated cell extract as compared to the control cell.
[076] The present invention provides a method for identifying a nucleotide sequence which is differentially regulated in a subject with cancer, comprising: hybridizing a nucleic acid sample corresponding to RNA obtained from the subject to a nucleic acid sample comprising one or more nucleic acid molecules of known identity; and measuring the hybridization of the nucleic acid sample to the one or more nucleic acid molecules of known identity, wherein a two-fold difference in the hybridization of the nucleic acid sample to the one or more nucleic acid molecules of known identity relative to a nucleic acid sample obtained from a subject without cancer is indicative of the differential expression of the nucleotide sequence in a subject with cancer.
[077] Generally, the present invention provides a method for identifying nucleic acid sequences which are differentially regulated in a subject with cancer comprising isolating messenger RNA from a subject, generating cRNA from the mRNA sample, hybridizing the cRNA to a microarray comprising a plurality of nucleic acid molecules stably associated with discrete locations on the array, and identifying patterns of hybridization of the cRNA to the array. According to the present invention, a nucleic acid molecule which hybridizes to a given location on the array is said to be differentially regulated if the hybridization signal is at least two-fold higher or lower than the hybridization signal at the same location on an identical array hybridized with a nucleic acid sample obtained from a subject that does not have cancer.
Microarrays for Determining the Level of Expression of Genes
[078] Determining gene expression levels may be accomplished utilizing microarrays. Generally, the following steps may be involved: (a) obtaining an mRNA sample from a subject and preparing labeled nucleic acids therefrom (the "target nucleic acids" or "targets"); (b) contacting the target nucleic acids with an array under conditions sufficient for the target nucleic acids to bind to the corresponding probes on the array, for example, by hybridization or specific binding; (c) optional removal of unbound targets from the array; (d) detecting the bound targets, and (e) analyzing the results, for example, using computer based analysis methods. As used herein, "nucleic acid probes" or "probes" are nucleic acids attached to the array, whereas "target nucleic acids" are nucleic acids that are hybridized to the array.
[079] Nucleic acid specimens may be obtained from a subject to be tested using either "invasive" or "non-invasive" sampling means. A sampling means is said to be "invasive" if it involves the collection of nucleic acids from within the skin or organs of an animal (including murine, human, ovine, equine, bovine, porcine, canine, or feline animal). Examples of invasive methods include, for example, blood collection, semen collection, needle biopsy, pleural aspiration, umbilical cord biopsy. Examples of such methods are discussed by Kim, et al., (J. Virol. 66:3879-3882, 1992); Biswas, et al., (Ann. NY Acad. Sci. 590:582-583, 1990); and Biswas, et al., (J. Clin. Microbiol. 29:2228-2233, 1991).
[080] In contrast, a "non-invasive" sampling means is one in which the nucleic acid molecules are recovered from an internal or external surface of the animal. Examples of such "non-invasive" sampling means include, for example, "swabbing," collection of tears, saliva, urine, fecal material, sweat or perspiration, hair.
[081] In one embodiment of the present invention, one or more cells from the subject to be tested are obtained and RNA is isolated from the cells. In a preferred embodiment, a sample of peripheral blood leukocytes (PBLs) cells is obtained from the subject. It is also possible to obtain a cell sample from a subject, and then to enrich the sample for a desired cell type. For example, cells may be isolated from other cells using a variety of techniques, such as isolation with an antibody binding to an epitope on the cell surface of the desired cell type. Where the desired cells are in a solid tissue, particular cells may be dissected, for example, by microdissection or by laser capture microdissection (LCM) (see, e.g., Bonner, et al., Science 278: 1481, 1997; Emmert-Buck, et al., Science 274:998, 1996; Fend, et al., Am. J. Path. 154:61, 1999; and Murakami, et al., Kidney Int. 58: 1346, 2000).
[082] RNA may be extracted from tissue or cell samples by a variety of methods, for example, guanidium thiocyanate lysis followed by CsCl centrifugation (Chirgwin, et al., Biochemistry 18:5294-5299, 1979). RNA from single cells may be obtained as described in methods for preparing cDNA libraries from single cells (see, e.g., Dulac, Curr. Top. Dev. Biol. 36:245, 1998; Jena, et al., J. Immunol. Methods 190: 199, 1996).
[083] The RNA sample can be further enriched for a particular species. In one embodiment, for example, poly(A)+ RNA may be isolated from an RNA sample. In another embodiment, the RNA population may be enriched for sequences of interest by primer-specific cDNA synthesis, or multiple rounds of linear amplification based on cDNA synthesis and template- directed in vitro transcription (see, e.g., Wang, et al., Proc. Natl. Acad. Sci. USA 86:9717, 1989; Dulac, et al., supra; Jena, et al., supra). In addition, the population of RNA, enriched or not in particular species or sequences, may be further amplified by a variety of amplification methods including, for example, PCR; ligase chain reaction (LCR) (see, e.g., Wu and Wallace, Genomics 4:560, 1989; Landegren, et al., Science 241 : 1077, 1988); self-sustained sequence replication (SSR) (see, e.g., Guatelli, et al., Proc. Natl. Acad. Sci. USA 87: 1874, 1990); nucleic acid based sequence amplification (NASBA) and transcription amplification (see, e.g., Kwoh, et al., Proc. Natl. Acad. Sci. USA 86: 1173, 1989). Methods for PCR technology are well known in the art (see, e.g., PCR Technology: Principles and Applications for DNA Amplification (ed. H. A. Erlich, Freeman Press, N.Y., N.Y., 1992); PCR Protocols: A Guide to Methods and Applications (eds. Innis, et al., Academic Press, San Diego, Calif., 1990); Mattila, et al., Nucleic Acids Res. 19:4967, 1991; Eckert, et al., PCR Methods and Applications 1: 17, 1991 ; PCR (eds. McPherson et al., IRL Press, Oxford); and U.S. Pat. No. 4,683,202). Methods of amplification are described, for example, by Ohyama, et al., (BioTechniques 29:530, 2000); Luo, et al., (Nat. Med. 5: 117, 1999); Hegde, et al., (BioTechniques 29:548, 2000); Kacharmina, et al., (Meth. Enzymol. 303:3, 1999); Livesey, et al., Curr. Biol. 10:301, 2000); Spirin, et al., (Invest. Ophtalmol. Vis. Sci. 40:3108, 1999); and Sakai, et al., (Anal. Biochem. 287:32, 2000). RNA amplification and cDNA synthesis may also be conducted in cells in situ (see, e.g., Eberwine, et al. Proc. Natl. Acad. Sci. USA 89:3010, 1992).
[084] The nucleic acid molecules may be labeled to permit detection of hybridization of the nucleic acid molecules to a microarray. That is, the probe may comprise a member of a signal producing system and thus, is detectable, either directly or through combined action with one or more additional members of a signal producing system. For example, the nucleic acids may be labeled with a fluorescently labeled dNTP (see, e.g., Kricka, 1992, Nonisotopic DNA Probe Techniques, Academic Press San Diego, Calif.), biotinylated dNTPs or rNTP followed by addition of labeled streptavidin, chemiluminescent labels, or isotopes. Another example of labels include "molecular beacons" as described in Tyagi and Kramer (Nature Biotech. 14:303, 1996). Hybridization may be also be determined, for example, by plasmon resonance (see, e.g., Thiel, et al. Anal. Chem. 69:4948, 1997).
[085] In one embodiment, a plurality (e.g., 2, 3, 4, 5, or more) of sets of target nucleic acids are labeled and used in one hybridization reaction ("multiplex" analysis). For example, one set of nucleic acids may correspond to RNA from one cell and another set of nucleic acids may correspond to RNA from another cell. The plurality of sets of nucleic acids may be labeled with different labels, for example, different fluorescent labels (e.g., fluorescein and rhodamine) which have distinct emission spectra so that they can be distinguished. The sets may then be mixed and hybridized simultaneously to one microarray (see, e.g., Shena, et al., Science 270:467-470, 1995).
[086] Microarrays for use according to the invention include one or more probes of genes characteristic of small molecule efficacy. In a preferred embodiment, the microarray comprises probes corresponding to one or more of genes selected from the group consisting of genes which are up-regulated in cancer and genes which are down-regulated in cancer. The microarray may comprise probes corresponding to at least 10, preferably at least 20, at least 50, at least 100 or at least 1000 genes characteristic of small molecule efficacy. [087] There may be one or more than one probe corresponding to each gene on a microarray. For example, a microarray may contain from 2 to 20 probes corresponding to one gene and preferably about 5 to 10. The probes may correspond to the full-length RNA sequence or complement thereof of genes characteristic of small molecule efficacy, or the probe may correspond to a portion thereof, which portion is of sufficient length to permit specific hybridization. Such probes may comprise from about 50 nucleotides to about 100, 200, 500, or 1000 nucleotides or more than 1000 nucleotides. As further described herein, microarrays may contain oligonucleotide probes, consisting of about 10 to 50 nucleotides, preferably about 15 to 30 nucleotides and more preferably about 20-25 nucleotides. The probes are preferably single-stranded and will have sufficient complementarity to its target to provide for the desired level of sequence specific hybridization.
[088] Typically, the arrays used in the present invention will have a site density of greater than 100 different probes per cm2. Preferably, the arrays will have a site density of greater than 500/cm2, more preferably greater than about 1000/cm2, and most preferably, greater than about 10,000/cm2. Preferably, the arrays will have more than 100 different probes on a single substrate, more preferably greater than about 1000 different probes, still more preferably, greater than about 10,000 different probes and most preferably, greater than 100,000 different probes on a single substrate.
[089] A number of different microarray configurations and methods for their production are known to those of skill in the art and are disclosed in U.S. Patent Nos: 5,242,974; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,445,934; 5,556,752; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,436,327; 5,472,672; 5,527,681; 5,529,756; 5,545,531; 5,554,501; 5,561,071 ; 5,571,639; 5,593,839; 5,624,711 ; 5,700,637; 5,744,305; 5,770,456; 5,770,722; 5,837,832; 5,856,101 ; 5,874,219; 5,885,837; 5,919,523; 6,022,963; 6,077,674; and 6,156,501 ; Shena, et al., Tibtech 16:301, 1998; Duggan, et al., Nat. Genet. 21 : 10, 1999; Bowtell, et al., Nat. Genet. 21:25, 1999; Lipshutz, et al., 21 Nature Genet. 20-24, 1999; Blanchard, et al., 11 Biosensors and Bioelectronics, 687-90, 1996; Maskos, et al., 21 Nucleic Acids Res. 4663-69, 1993; Hughes, et al., Nat. Biotechol. (2001) 19:342; the disclosures of which are herein incorporated by reference. Patents describing methods of using arrays in various applications include: U.S. Pat. Nos. 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; 5,848,659; and 5,874,219; the disclosures of which are herein incorporated by reference. [090] Arrays preferably include control and reference nucleic acids. Control nucleic acids include, for example, prokaryotic genes such as bioB, bioC and bioD, ere from PI bacteriophage or polyA controls, such as dap, lys, phe, thr, and trp. Reference nucleic acids allow the normalization of results from one experiment to another and the comparison of multiple experiments on a quantitative level. Exemplary reference nucleic acids include housekeeping genes of known expression levels, for example, GAPDH, hexokinase, and actin.
[091] In one embodiment, an array of oligonucleotides may be synthesized on a solid support. Exemplary solid supports include glass, plastics, polymers, metals, metalloids, ceramics, organics, etc. Using chip masking technologies and photoprotective chemistry, it is possible to generate ordered arrays of nucleic acid probes. These arrays, which are known, for example, as "DNA chips" or very large scale immobilized polymer arrays ("VLSIPS™" arrays), may include millions of defined probe regions on a substrate having an area of about 1 cm2 to several cm2, thereby incorporating from a few to millions of probes (see, e.g., U.S. Patent No. 5,631,734).
[092] To compare expression levels, labeled nucleic acids may be contacted with the array under conditions sufficient for binding between the target nucleic acid and the probe on the array. In a preferred embodiment, the hybridization conditions may be selected to provide for the desired level of hybridization specificity; that is, conditions sufficient for hybridization to occur between the labeled nucleic acids and probes on the microarray.
[093] Hybridization may be carried out in conditions permitting essentially specific hybridization. The length and GC content of the nucleic acid will determine the thermal melting point and thus, the hybridization conditions necessary for obtaining specific hybridization of the probe to the target nucleic acid. These factors are well known to a person of skill in the art, and may also be tested in assays. An extensive guide to nucleic acid hybridization may be found in Tijssen, et al. (Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 24: Hybridization With Nucleic Acid Probes, P. Tijssen, ed. Elsevier, N.Y., (1993)).
[094] The methods described above result in the production of hybridization patterns of labeled target nucleic acids on the array surface. The resultant hybridization patterns of labeled nucleic acids may be visualized or detected in a variety of ways, with the particular manner of detection selected based on the particular label of the target nucleic acid. Representative detection means include scintillation counting, autoradiography, fluorescence measurement, colorimetric measurement, light emission measurement, light scattering, and the like.
[095] One such method of detection utilizes an array scanner that is commercially available (Affymetrix, Santa Clara, CA), for example, the 417™ Arrayer, the 418™ Array Scanner, or the Agilent GeneArray™ Scanner. This scanner is controlled from a system computer with an interface and easy-to-use software tools. The output may be directly imported into or directly read by a variety of software applications. Preferred scanning devices are described in, for example, U.S. Patent Nos. 5,143,854 and 5,424,186.
[096] For fluorescent labeled probes, the fluorescence emissions at each site of a transcript array may be, preferably, detected by scanning confocal laser microscopy. Alternatively, a laser may be used that allows simultaneous specimen illumination at wavelengths specific to the two fluorophores and emissions from the two fluorophores may be analyzed simultaneously (see, e.g., Shalon, et al., Genome Res. 6:639-645, 1996). In a preferred embodiment, the arrays may be scanned with a laser fluorescent scanner with a computer controlled X-Y stage and a microscope objective. Fluorescence laser scanning devices are described in Shalon, et al., supra.
[097] Various algorithms are available for analyzing gene expression data, for example, the type of comparisons to perform. In certain embodiments, it is desirable to group genes that are co-regulated. This allows for the comparison of large numbers of profiles. A preferred embodiment for identifying such groups of genes involves clustering algorithms (for reviews of clustering algorithms, see, e.g., Fukunaga, 1990, Statistical Pattern Recognition, 2nd Ed., Academic Press, San Diego; Everitt, 1974, Cluster Analysis, London: Heinemann Educ. Books; Hartigan, 1975, Clustering Algorithms, New York: Wiley; Sneath and Sokal, 1973, Numerical Taxonomy, Freeman; Anderberg, 1973, Cluster Analysis for Applications, Academic Press: New York).
Biomarker Discovery
[098] Expression patterns may be used to derive a panel of biomarkers that can be used to predict the efficacy of drug treatment in the patients. The biomarkers may consist of gene expression levels from microarray experiments on RNA isolated from biological samples, RNA isolated from frozen samples of tumor biopsies, or mass spectrometry-derived protein masses in the serum. [099] Although the precise mechanism for data analysis will depend upon the exact nature of the data, a typical procedure for developing a panel of biomarkers is as follows. The data (gene expression levels or mass spectra) are collected for each patient prior to treatment. As the study progresses, the patients are classified according to their response to the drug treatment; either as efficacious or non-efficacious. Multiple levels of efficacy can be accommodated in a data model, but a binary comparison is considered optimal, particularly if the patient population is less than several hundred. Assuming adequate numbers of patients in each class, the protein and/or gene expression data may be analyzed by a number of techniques known in the art. Many of the techniques are derived from traditional statistics as well from the field of machine learning. These techniques serve two purposes:
1. Reduce the dimensionality of data - In the case of mass spectra or gene expression microarrays, data is reduced from many thousands of individual data points to bout three to ten. The reduction is based upon the predictive power of the data points when taken as a set.
2. Training - These three to ten data points are then used to train multiple machine learning algorithms which then "learn" to recognize, in this case, patterns of protein masses or gene expression which distinguish efficacious drug treatment from non-efficacious. All patient samples can be used to train the algorithms.
[0100] The resulting, trained, algorithms are then tested in order to measure their predictive power. Typically, when less than many hundreds of training examples are available, some form of cross-validation is performed. To illustrate, consider a ten-fold cross validation. In this case, patient samples are randomly assigned to one of ten bins. In the first round of validation the samples in nine of the bins are used for training and the remaining samples in the tenth bin are used to test the algorithm. This is repeated an additional nine times, each time leaving out the samples in a different bin for testing. The results (correct predictions and errors) from all ten rounds are combined and the predictive power is then assessed. Different algorithms, as well as different panels, may be compared in this way for this study. The "best" algorithm/panel combination will then be selected. This "smart" algorithm may then be used in future studies to select the patients that are most likely to respond to treatment.
[0101] Many algorithms benefit from additional information taken for the patients. For example, gender or age could be used to improve predictive power. Also, data transformations such as normalization and smoothing may be used to reduce noise. Because of this, a large number of algorithms may be trained using many different parameters in order to optimize the outcome. If predictive patterns exist in the data, it is likely that an optimal, or near-optimal, "smart" algorithm can be developed. If more patient samples become available, the algorithm can be retrained to take advantage of the new data.
[0102] As an example using mass spectrometry, plasma (1 μΐ) may be applied to a hydrophobic SELDI-target, washed extensively in water, and analyzed by the SELDI-Tof mass spectrometer. This may be repeated on 100 or more patient samples. The protein profiles resulting from the intensities of some 16,000 m/z values in each sample would be statistically analyzed in order to identify sets of specific m/z values that are predictive of drug efficacy. Identical experiments using other SELDI-targets, such as ion-exchange or IMAC surfaces, could also be conducted. These will capture different subsets of the proteins present in plasma. Furthermore, the plasma may be denatured and prefractionated prior to application onto the SELDI target.
Diagnostic & Prognostic Assays
[0103] The present invention provides methods for determining whether a subject is at risk for developing a disease or condition characterized by unwanted cell proliferation by detecting biomarkers (e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF), that is, nucleic acids and/or polypeptide markers for cancer.
[0104] In clinical applications, human tissue samples may be screened for the presence and/or absence of biomarkers identified herein. Such samples could consist of needle biopsy cores, surgical resection samples, lymph node tissue, or serum. For example, these methods include obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich tumor cells to about 80% of the total cell population. In certain embodiments, nucleic acids extracted from these samples may be amplified using techniques well known in the art. The levels of selected markers detected would be compared with statistically valid groups of metastatic, non-metastatic malignant, benign, or normal tissue samples.
[0105] In one embodiment, the diagnostic method comprises determining whether a subject has an abnormal mRNA and/or protein level of the biomarkers (e.g., PLGF, CALX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF), such as by Northern blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, immunoprecipitation, Western blot hybridization, or immunohistochemistry. According to the method, cells may be obtained from a subject and the levels of the biomarkers, protein, or mRNA level, are determined and compared to the level of these markers in a healthy subject. An abnormal level of the biomarker polypeptide or mRNA levels is likely to be indicative of cancer.
[0106] In one embodiment, the method comprises using a nucleic acid probe to determine the presence of cancerous cells in a tissue from a patient. Specifically, the method comprises:
1. providing a nucleic acid probe comprising a nucleotide sequence at least 10 nucleotides in length, preferably at least 15 nucleotides, more preferably, 25 nucleotides, and most preferably at least 40 nucleotides, and up to all or nearly all of the coding sequence which is complementary to a portion of the coding sequence of a nucleic acid sequence and is differentially expressed in tumors cells;
2. obtaining a tissue sample from a patient potentially comprising cancerous cells;
3. providing a second tissue sample containing cells substantially all of which are noncancerous;
4. contacting the nucleic acid probe under stringent conditions with RNA of each of said first and second tissue samples (e.g., in a Northern blot or in situ hybridization assay); and
5. comparing (a) the amount of hybridization of the probe with RNA of the first tissue sample, with (b) the amount of hybridization of the probe with RNA of the second tissue sample; wherein a statistically significant difference in the amount of hybridization with the RNA of the first tissue sample as compared to the amount of hybridization with the RNA of the second tissue sample is indicative of the presence of cancerous cells in the first tissue sample.
[0107] In one aspect, the method comprises in situ hybridization with a probe derived from a given marker nucleic acid sequence (e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF). The method comprises contacting the labeled hybridization probe with a sample of a given type of tissue potentially containing cancerous or pre-cancerous cells as well as normal cells, and determining whether the probe labels some cells of the given tissue type to a degree significantly different (e.g., by at least a factor of two, or at least a factor of five, or at least a factor of twenty, or at least a factor of fifty) than the degree to which it labels other cells of the same tissue type.
[0108] Also within the invention is a method of determining the phenotype of a test cell from a given human tissue, for example, whether the cell is (a) normal, or (b) cancerous or precancerous, by contacting the mRNA of a test cell with a nucleic acid probe at least 12 nucleotides in length, preferably at least 15 nucleotides, more preferably at least 25 nucleotides, and most preferably at least 40 nucleotides, and up to all or nearly all of a sequence which is complementary to a portion of the coding sequence of a nucleic acid sequence, and which is differentially expressed in tumor cells as compared to normal cells of the given tissue type; and determining the approximate amount of hybridization of the probe to the mRNA, an amount of hybridization either more or less than that seen with the mRNA of a normal cell of that tissue type being indicative that the test cell is cancerous or precancerous.
[0109] Alternatively, the above diagnostic assays may be carried out using antibodies to detect the protein product encoded by the marker nucleic acid sequence (e.g., PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF). Accordingly, in one embodiment, the assay would include contacting the proteins of the test cell with an antibody specific for the gene product of a nucleic acid, the marker nucleic acid being one which is expressed at a given control level in normal cells of the same tissue type as the test cell, and determining the approximate amount of immunocomplex formation by the antibody and the proteins of the test cell, wherein a statistically significant difference in the amount of the immunocomplex formed with the proteins of a test cell as compared to a normal cell of the same tissue type is an indication that the test cell is cancerous or pre-cancerous. Preferably, the antibody is specific for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF, especially its extracellular domain.
[0110] The method for producing polyclonal and/or monoclonal antibodies which specifically bind to polypeptides useful in the present invention is known to those of skill in the art and may be found in, for example, Dymecki, et al., (J. Biol. Chem. 267:4815, 1992); Boersma & Van Leeuwen, (J. Neurosci. Methods 51:317, 1994); Green, et al., (Cell 28:477, 1982); and Arnheiter, et al., (Nature 294:278, 1981). [0111] Another such method includes the steps of: providing an antibody specific for the gene product of a marker nucleic acid sequence, the gene product being present in cancerous tissue of a given tissue type at a level more or less than the level of the gene product in noncancerous tissue of the same tissue type; obtaining from a patient a first sample of tissue of the given tissue type, which sample potentially includes cancerous cells; providing a second sample of tissue of the same tissue type (which may be from the same patient or from a normal control, e.g. another individual or cultured cells), this second sample containing normal cells and essentially no cancerous cells; contacting the antibody with protein (which may be partially purified, in lysed but unfractionated cells, or in situ) of the first and second samples under conditions permitting immunocomplex formation between the antibody and the marker nucleic acid sequence product present in the samples; and comparing (a) the amount of immunocomplex formation in the first sample, with (b) the amount of immunocomplex formation in the second sample, wherein a statistically significant difference in the amount of immunocomplex formation in the first sample less as compared to the amount of immunocomplex formation in the second sample is indicative of the presence of cancerous cells in the first sample of tissue.
[0112] The subject invention further provides a method of determining whether a cell sample obtained from a subject possesses an abnormal amount of marker polypeptide which comprises (a) obtaining a cell sample from the subject, (b) quantitatively determining the amount of the marker polypeptide in the sample so obtained, and (c) comparing the amount of the marker polypeptide so determined with a known standard, so as to thereby determine whether the cell sample obtained from the subject possesses an abnormal amount of the marker polypeptide. Such marker polypeptides may be detected by immunohistochemical assays, dot-blot assays, ELISA, and the like.
[0113] Immunoassays are commonly used to quantitate the levels of proteins in cell samples, and many other immunoassay techniques are known in the art. The invention is not limited to a particular assay procedure, and therefore, is intended to include both homogeneous and heterogeneous procedures. Exemplary immunoassays which may be conducted according to the invention include fluorescence polarization immunoassay (FPIA), fluorescence immunoassay (FIA), enzyme immunoassay (EIA), nephelometric inhibition immunoassay (NIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA). An indicator moiety, or label group, may be attached to the subject antibodies and is selected so as to meet the needs of various uses of the method which are often dictated by the availability of assay equipment and compatible immunoassay procedures. Conditions suitable for the formation of antibody- antigen complexes are well known in the art. General techniques to be used in performing the various immunoassays noted above are known to those of ordinary skill in the art. See generally E. Maggio, Enzyme-Immunoassay, (1980) (CRC Press, Inc., Boca Raton, Fla.); see also, e.g., U.S. Pat. No. 4,727,022 (Skold et al., "Methods for Modulating Ligand-Receptor Interactions and their Application"); U.S. Pat. No. 4,659,678 (Forrest et al., "Immunoassay of Antigens"); U.S. Pat. No. 4,376,110 (David et al., "Immunometric Assays Using Monoclonal Antibodies"). Conditions suitable for the formation of reagent- antibody complexes are well described. See id. Monoclonal antibodies of the invention may be used in a "two-site" or "sandwich" assay, with a single cell line serving as a source for both the labeled monoclonal antibody and the bound monoclonal antibody. Such assays are described in U.S. Pat. No. 4,376,110. The concentration of detectable reagent should be sufficient such that the binding of mutant BCR-ABL is detectable compared to background. It will be understood that more than one antibody may be used in the practice of the above-described methods.
[0114] In another embodiment, the level of the encoded product, or alternatively the level of the polypeptide, in a biological fluid (e.g., blood or urine) of a patient may be determined as a way of monitoring the level of expression of the marker nucleic acid sequence in cells of that patient. Such a method would include the steps of obtaining a sample of a biological fluid from the patient, contacting the sample (or proteins from the sample) with an antibody specific for an encoded marker polypeptide, and determining the amount of immune complex formation by the antibody, with the amount of immune complex formation being indicative of the level of the marker encoded product in the sample. This determination is particularly instructive when compared to the amount of immune complex formation by the same antibody in a control sample taken from a normal individual or in one or more samples previously or subsequently obtained from the same person.
[0115] In another embodiment, the method may be used to determine the amount of marker polypeptide present in a cell, which in turn may be correlated with progression of a hyperproliferative disorder. The level of the marker polypeptide may be used predictively to evaluate whether a sample of cells contains cells which are, or are predisposed towards becoming, transformed cells. Moreover, the subject method may be used to assess the phenotype of cells which are known to be transformed, the phenotyping results being useful in planning a particular therapeutic regimen. For example, very high levels of the marker polypeptide in sample cells is a powerful diagnostic and prognostic marker for a cancer. The observation of marker polypeptide levels may be utilized in decisions regarding, for example, the use of more aggressive therapies.
[0116] As set out above, one aspect of the present invention relates to diagnostic assays for determining, in the context of cells isolated from a patient, if the level of a marker polypeptide is significantly reduced in the sample cells. The term "significantly reduced" refers to a cell phenotype wherein the cell possesses a reduced cellular amount of the marker polypeptide relative to a normal cell of similar tissue origin. For example, a cell may have less than about 50%, 25%, 10%, or 5% of the marker polypeptide compared to that of a normal control cell. In particular, the assay evaluates the level of marker polypeptide in the test cells, and, preferably, compares the measured level with marker polypeptide detected in at least one control cell, for example, a normal cell and/or a transformed cell of known phenotype.
[0117] Of particular importance to the subject invention is the ability to quantitate the level of marker polypeptide as determined by the number of cells associated with a normal or abnormal marker polypeptide level. The number of cells with a particular marker polypeptide phenotype may then be correlated with patient prognosis. In one embodiment of the invention, the marker polypeptide phenotype of a lesion is determined as a percentage of cells in a biopsy which are found to have abnormally high/low levels of the marker polypeptide. Such expression may be detected by immunohistochemical assays, dot-blot assays, ELISA, and the like.
[0118] Where tissue samples are employed, immunohistochemical staining may be used to determine the number of cells having the marker polypeptide phenotype. For such staining, a multiblock of tissue may be taken from the biopsy or other tissue sample and subjected to proteolytic hydrolysis, employing such agents as protease K or pepsin. In certain embodiments, it may be desirable to isolate a nuclear fraction from the sample cells and detect the level of the marker polypeptide in the nuclear fraction.
[0119] The tissue samples are fixed by treatment with a reagent such as formalin, glutaraldehyde, methanol, or the like. The samples are then incubated with an antibody, preferably a monoclonal antibody, with binding specificity for the marker polypeptides. This antibody may be conjugated to a label for subsequent detection of binding. Samples are incubated for a time sufficient for formation of the immunocomplexes. Binding of the antibody is then detected by virtue of a label conjugated to this antibody. Where the antibody is unlabeled, a second labeled antibody may be employed, for example, which is specific for the isotype of the anti-marker polypeptide antibody. Examples of labels which may be employed include radionuclides, fluorescers, chemiluminescers, enzymes, and the like.
[0120] Where enzymes are employed, the substrate for the enzyme may be added to the samples to provide a colored or fluorescent product. Examples of suitable enzymes for use in conjugates include horseradish peroxidase, alkaline phosphatase, malate dehydrogenase, and the like. Where not commercially available, such antibody-enzyme conjugates are readily produced by techniques known to those skilled in the art.
[0121] In one embodiment, the assay is performed as a dot blot assay. The dot blot assay finds particular application where tissue samples are employed as it allows determination of the average amount of the marker polypeptide associated with a single cell by correlating the amount of marker polypeptide in a cell-free extract produced from a predetermined number of cells.
[0122] It is well established in the cancer literature that tumor cells of the same type (e.g., breast and/or colon tumor cells) may not show uniformly increased expression of individual oncogenes or uniformly decreased expression of individual tumor suppressor genes. There may also be varying levels of expression of a given marker gene even between cells of a given type of cancer, further emphasizing the need for reliance on a battery of tests rather than a single test. Accordingly, in one aspect, the invention provides for a battery of tests utilizing a number of probes of the invention, in order to improve the reliability and/or accuracy of the diagnostic test.
[0123] In one embodiment, the present invention also provides a method wherein nucleic acid probes are immobilized on a DNA chip in an organized array. Oligonucleotides may be bound to a solid support by a variety of processes, including lithography. For example, a chip may hold up to 250,000 oligonucleotides. These nucleic acid probes comprise a nucleotide sequence at least about 12 nucleotides in length, preferably at least about 15 nucleotides, more preferably at least about 25 nucleotides, and most preferably at least about 40 nucleotides, and up to all or nearly all of a sequence which is complementary to a portion of the coding sequence of a marker nucleic acid sequence and is differentially expressed in tumor cells. The present invention provides significant advantages over the available tests for various cancers, because it increases the reliability of the test by providing an array of nucleic acid markers on a single chip.
[0124] The method includes obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich tumor cells to about 80% of the total cell population. The DNA or RNA is then extracted, amplified, and analyzed with a DNA chip to determine the presence of absence of the marker nucleic acid sequences.
[0125] In one embodiment, the nucleic acid probes are spotted onto a substrate in a two- dimensional matrix or array. Samples of nucleic acids may be labeled and then hybridized to the probes. Double-stranded nucleic acids, comprising the labeled sample nucleic acids bound to probe nucleic acids, may be detected once the unbound portion of the sample is washed away.
[0126] The probe nucleic acids may be spotted on substrates including glass, nitrocellulose, etc. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. The sample nucleic acids can be labeled using radioactive labels, fluorophores, chromophores, etc.
[0127] Techniques for constructing arrays and methods of using these arrays are described, for example, in EP No. 0 799 897; PCT No. WO 97/292 12; PCT No. WO 97127317; EP No. 0 785 280; PCT No. WO 97/02357; U.S. Pat. No. 5,593,839; U.S. Pat. No. 5,578,832; EP No. 0 728 520; U.S. Pat. No. 5,599,695; EP No. 0 721 016; U.S. Pat. No. 5,556,752; PCT No. WO 95/22058; and U.S. Pat. No. 5,631,734.
[0128] Further, arrays may be used to examine differential expression of genes and may be used to determine gene function. For example, arrays of nucleic acid sequences may be used to determine if any of the nucleic acid sequences are differentially expressed between normal cells and cancer cells. Increased expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, may indicate a cancer-specific protein.
[0129] In one embodiment, nucleic acid molecules may be used to generate microarrays on a solid surface (e.g., a membrane) such that the arrayed nucleic acid molecules may be used to determine if any of the nucleic acids are differentially expressed between normal cells or tissue and cancerous cells or tissue. In one embodiment, the nucleic acid molecules of the invention may be cDNA or may be used to generate cDNA molecules to be subsequently amplified by PCR and spotted on nylon membranes. The membranes may then be reacted with radiolabeled target nucleic acid molecules obtained from equivalent samples of cancerous and normal tissue or cells. Methods of cDNA generation and microarray preparation are known to those of skill in the art and may be found, for example, in Bertucci, et al., (Hum. Mol. Genet. 8:2129, 1999); Nguyen, et al., (Genomics 29:207, 1995); Zhao, et al., (Gene 156:207); Gress, et al., (Mammalian Genome 3:609, 1992); Zhumabayeva, et al., (Biotechniques 30: 158, 2001); and Lennon, et al., (Trends Genet. 7:314, 1991).
[0130] In yet another embodiment, the invention contemplates using a panel of antibodies which are generated against the marker polypeptides of this invention. Preferably, the antibodies are generated against PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF. Such a panel of antibodies may be used as a reliable diagnostic probe for cancer. The assay of the present invention comprises contacting a biopsy sample containing cells, for example, lung cells, with a panel of antibodies to one or more of the encoded products to determine the presence or absence of the marker polypeptides.
[0131] The diagnostic methods of the subject invention may also be employed as follow-up to treatment, for example, quantitation of the level of marker polypeptides may be indicative of the effectiveness of current or previously employed cancer therapies as well as the effect of these therapies upon patient prognosis.
[0132] In addition, the marker nucleic acids or marker polypeptides may be utilized as part of a diagnostic panel for initial detection, follow-up screening, detection of reoccurrence, and post-treatment monitoring for chemotherapy or surgical treatment.
[0133] Accordingly, the present invention makes available diagnostic assays and reagents for detecting gain and/or loss of marker polypeptides from a cell in order to aid in the diagnosis and phenotyping of proliferative disorders arising from, for example, tumorigenic transformation of cells.
[0134] The diagnostic assays described above may be adapted to be used as prognostic assays, as well. Such an application takes advantage of the sensitivity of the assays of the invention to events which take place at characteristic stages in the progression of a tumor. For example, a given marker gene may be up- or down-regulated at a very early stage, perhaps before the cell is irreversibly committed to developing into a malignancy, while another marker gene may be characteristically up- or down-regulated only at a much later stage. Such a method could involve the steps of contacting the mRNA of a test cell with a nucleic acid probe derived from a given marker nucleic acid which is expressed at different characteristic levels in cancerous or precancerous cells at different stages of tumor progression, and determining the approximate amount of hybridization of the probe to the mRNA of the cell, such amount being an indication of the level of expression of the gene in the cell, and thus an indication of the stage of tumor progression of the cell; alternatively, the assay may be carried out with an antibody specific for the gene product of the given marker nucleic acid, contacted with the proteins of the test cell. A battery of such tests will disclose not only the existence and location of a tumor, but also will allow the clinician to select the mode of treatment most appropriate for the tumor, and to predict the likelihood of success of that treatment.
[0135] The methods of the invention may also be used to follow the clinical course of a tumor. For example, the assay of the invention may be applied to a tissue sample from a patient; following treatment of the patient for the cancer, another tissue sample is taken and the test repeated. Successful treatment will result in either removal of all cells which demonstrate differential expression characteristic of the cancerous or precancerous cells, or a substantial increase in expression of the gene in those cells, perhaps approaching or even surpassing normal levels.
Predictive Assays
[0136] Laboratory-based assays, which can predict clinical benefit from a given anti-cancer agent, will greatly enhance the clinical management of patients with cancer. In order to assess this effect, a biomarker associated with the anti-cancer agent may be analyzed in a biological sample (e.g., tumor sample, plasma) before, during, and following treatment.
[0137] For example, the expression of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF, polypeptide may be detected in plasma. Thus, changes in the baseline plasma concentration of these polypeptides may be monitored in patients with cancer. For example, increased levels of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD or ANG2 and decreased levels of SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF can be associated with Regorafenib efficacy.
[0138] Ligands to receptors that may be inhibited by Regorafenib (VEGF-A, VEGF-D PLGF, ANG2) generally increased in response to Regorafenib. Some pro-angiogenic factors (HGF, bFGF) decreased in response to Regorafenib. Soluble forms of receptors that may be targeted by Regorafenib generally decreased in response to Regorafenib (sVEGFR2, sTIE- l,s-c-Kit). Proteins that may indicate cell death (CK18M30, CytC) or hypoxia (CA9) increased in response to Regorafenib. Metalloproteinase inhibitors TIMP2 and TIMP4 decreased in response to Regorafenib. Regorafenib increased the levels of P1GF in 96% of the patients and decreased the levels of sVEGFR2 and TIMP2 in 100% of patients.
[0139] Additionally, the polypeptide levels may also be monitored by quantitative immunohistochemistry using paraffin-embedded tumor biopsies.
[0140] Another approach to monitor treatment is an evaluation of serum proteomic spectra. Specifically, plasma samples may be subjected to mass spectroscopy (e.g., surface-enhanced laser desorption and ionization) and a proteomic spectra may be generated for each patient. A set of spectra, derived from analysis of plasma from patients before and during treatment, may be analyzed by an iterative searching algorithm, which can identify a proteomic pattern that completely discriminates the treated samples from the untreated samples. The resulting pattern may then be used to predict the clinical benefit following treatment.
[0141] Global gene expression profiling of biological samples (e.g., tumor biopsy samples, blood samples) and bioinformatics-driven pattern identification may be utilized to predict clinical benefit and sensitivity, as well as development of resistance to an anti-cancer agent. For example, RNA isolated from cells derived from whole blood from patients before and during treatment may be used to generate blood cell gene expression profiles utilizing Affymetrix GeneChip technology and algorithms. These gene expression profiles may then predict the clinical benefit from treatment with a particular anti-cancer agent.
[0142] Analysis of the biochemical composition of urine by ID ^-NMR (Nuclear Magnetic Resonance) may also be utilized as a predictive assay. Pattern recognition techniques may be used to evaluate the metabolic response to treatment with an anti-cancer agent and to correlate this response with clinical endpoints. The biochemical or endogenous metabolites excreted in urine have been well-characterized by proton NMR for normal subjects (Zuppi, et al., Clin Chim Acta 265:85-97, 1997). These metabolites (approximately 30-40) represent the by-products of the major metabolic pathways, such as the citric acid and urea cycles. Drug-, disease-, and genetic-stimuli have been shown to produce metabolic-specific changes in baseline urine profiles that are indicative of the timeline and magnitude of the metabolic response to the stimuli. These analyses are multi-variant and therefore use pattern recognition techniques to improve data interpretation. Urinary metabolic profiles may be correlated with clinical endpoints to determine the clinical benefit. [0143] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the following invention to its fullest extent. The following specific preferred embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
[0144] In the forgoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.
BRIEF DESCRIPTION OF THE DRAWING
[0145] Figure 1 is six graphs showing the Regorafenib-mediated changes in PLGF,
SVEGFR2 and TIMP2.
[0146] Figure 2 is three graphs showing the predictive value of raf mediated changes in plasma protein levels.
[0147] Figure 3 is five graphs showing the predicative value of base line plasma protein levels
EXAMPLES
[0148] The invention will be explained below with reference to the following non-limiting examples.
[0149] Patients and methods: Patients selected for treatment with Regorafenib and analysis for biomarkers had previously untreated metastatic or unresectable clear cell RCC. These patients received oral Regorafenib (160 mg/day) in repeating cycles of 3 weeks on / 1 week off until disease progression or until patients met the criteria for removal from study. Primary efficacy endpoint was overall objective response rate. Secondary efficacy endpoints included overall survival, progression-free survival (PFS), time to progression, duration of response, duration of stable disease, disease control rate and clinical benefit rate. Safety was assessed by analysis of adverse events (AEs) and changes in laboratory, vital signs, and electrocardiogram measurements.
[0150] Potential plasma protein biomarkers were quantified using multiplex bead immunoassays. Plasma was obtained at baseline and after 15 days of daily Regorafenib treatment from 29 patients (pts) with previously untreated unresectable or metastatic RCC enrolled in a Phase II trial that demonstrated Regorafenib clinical activity. Biomarkers examined included soluble forms of receptors inhibited by Regorafenib, for example, soluble VEGF receptor-2 (sVEGFR2), soluble KIT (sKIT) and their ligands, for example, VEGF, SCF. Various other molecules associated with angiogenesis (for example, HGF), hypoxia (for example, CAFX), apoptosis (for example, CK18M30, CYTC) and tumor invasion (for example, TIMP2) were also examined. Statistical analyses were performed to determine if potential biomarker levels changed in response to Regorafenib exposure. In addition, correlations between biomarkers and clinical response, indicated by maximum change in tumor size, were examined.
[0151] Results indicate that a subset of biomarkers was altered by exposure to Regorafenib. PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2 levels were increased. The levels of sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, SCF were decreased. The most consistent, robust changes were in PLGF (increase in 27/28 pts (96%); median fold change of +3.3; p<0.0001) and sVEGFR2 (decrease in 28/28 pts(100%); median fold change of -1.6; p<0.0001) and TIMP2 (decrease in 28/28 pts(100%)).
[0152] These results are summarized in Figure Iwhere the left hand panels show the levels of plasma proteins that were altered in response to Regorafenib administration (box and whiskers plots). The right-hand panels show Regorafenib-mediated changes in individual patients. "Pre" indicates plasma collected at baseline prior to Regorafenib treatment and "Post" indicates plasma collected after 15 consecutive days of Regorafenib administrations.
[0153] Notably, circulating levels of several receptors that may be targeted by Regorafenib (sVEGFR2, sKIT, sTIEl) were decreased. Several members of the VEGF family of ligands (PLGF, VEGFA, VEGFD) were increased. Potential biomarkers that did not change included ANG1, GCSF, HGF, IL16, MCSF, sMCSFR, OPN, PDGFAA, AB and BB, SDFloc, sTIE2, TIMP1 and 3, VEGFC, sVEGFRl and sVEGFR3.
[0154] Three biomarkers whose levels were modulated by Regorafenib (sKIT, CYTC, CK18M30) exhibited a significant correlation between degree of change and clinical response as summarized below in the following table.
Predictive value of Regorafenib-mediated changes in plasma protein levels
Clinical Response Protein
Best response CK18M30
SD+PD (n=15) vs PR(n=13);
ANOVA Maximum tumor shrinkage CK18M30, s-c-Kit
<40 (n=13) vs> 40 (n=15);
ANOVA
Maximum tumor shrinkage CK18M30, CytC
Continuous variable : Spearman
Rank correlation
[0155] Changes in the level of CK18M30 (a protein released in response to epithelial cell death) correlated with clinical response to Regorafenib when the clinical endpoint was either maximum tumor shrinkage or best response.
[0156] Changes in the level of CytC (another protein released in response to epithelial cell death) correlated with clinical response to Regorafenib when the maximum tumor shrinkage was examined as a continuous variable.
[0157] Changes in the level of s-c-kit (a kinase receptor targeted by Regorafenib) correlated with clinical response to Regorafenib when patients were analyzed as 2 clinical response groups based on maximum tumor shrinkage.
[0158] Figure 2 shows the changes in Regorafenib-mediated plasma levels of CK18M30 in patients grouped based on maximum tumor shrinkage and best response, and changes in s-c- kit based on maximum tumor shrinkage.
[0159] In preferred embodiments of the method of this invention, the degree change(s) in sKIT, CYTC or CK18M30 levels is/are correlated with clinical response to Regorafenib.
[0160] Baseline levels of a subset of biomarkers (IL16, SCF, HGF, TIMP2) were also significantly correlated with clinical response (best response and tumor shrinkage) to Regorafenib as summarized in the table below.
Predictive value of baseline plasma protein levels
Clinical Response Protein
Best response sTIEl,M-CSF, FasL
SD+PD (n=15) vs PR(n=13);
ANOVA Maximum tumor shrinkage sTIEl, TIMP2
<40 (n=13) vs> 40 (n=15);
ANOVA
Maximum tumor shrinkage TIMP2,SCF, HGFJL-16
Continuous variable : Spearman
Rank correlation
[0161] Higher baseline levels of sTIEl(a kinase receptor that may be targeted by Regorafenib), M-CSF and SCF(Ligands for receptors that may be targeted by Regorafenib) correlated with better clinical response to Regorafenib. Other proteins whose baseline level correlated with clinical response to Regorafenib include Fasl, IL-16, the pro-angiogenic factor HGF and the metalloproteinase inhibitor TIMP2. Figure 3 shows the correlation of baseline plasma levels of sTIEl, M-CSF, TIMP2 and FasL with clinical response to Regorafenib.
[0162] In other preferred embodiments of the method of this invention, baseline levels of IL16, SCF, HGF or TIMP2 are associated with clinical response to Regorafenib. Assays testing for these biomarkers may be advantageously employed to identify patients that would be likely to respond to Regorafenib.
[0163] These results suggest potential mechanisms for the anticancer activity of Regorafenib (for example, anti- angiogenic activity). The methods and compositions of the instant application allow identification of biomarkers that are potentially predictive of clinical response in patients with RCC.
[0164] In addition the protocol above, the following protocol can be used to investigate the effects of Regorafenib on overall survival for patients with cancers other than RCC, and evaluate the association between the biomarkers above and patient outcome.
[0165] Patient samples are first collected for the identification of candidate biomarkers, such as archival tumor biopsy specimens, whole blood, plasma, and urine. All analyses should be carried out under IRB-approved protocols. Tissue specimens can optionally be analyzed for VHL gene mutation status (only for patients consenting to genetic analysis) by DNA sequencing, and phospho-ERK (pERK) levels by immunohistochemistry (IHC). mRNA can be isolated from blood and analyzed by microarrays for gene expression profiles that correlate with patient outcome. Additionally or alternatively, a mass spectrometry-based approach can be used to assess plasma for a protein signature, and urine can optionally be analyzed by ^-NMR for patterns of small molecules that correlate with patient outcome.
[0166] Pre- and post-treatment plasma samples are analyzed by ELISA for PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF, and changes in these molecules related to Regorafenib treatment are investigated.
[0167] The PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF levels in patients can be examined to identify correlations with clinical outcome (time to death (TTD) and progression-free survival (PFS) using a Cox regression analysis. Baseline levels of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF are first determined and changes in the baseline levels are determined after treatment, preferably at about week 18 of treatment. The effects observed were adjusted for age, gender, ECOG status or Motzer score. These adjustments were minimal.
[0168] Without further elaboration, it is believed that one skilled in the art can, using the preceding description and information available in the art, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
[0169] The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
[0170] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
[0171] The topic headings set forth above and below are meant as guidance where certain information can be found in the application, but are not intended to be the only source in the application where information on such topic can be found. All publications and patents cited above are incorporated herein by reference.

Claims

We claim:
Claim 1. A method for determining and/or monitoring the response of a cancer patient to Regorafenib, comprising detecting the level or activity of at least one polypeptide biomarker which is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, SCF or a combination thereof in a patient specimen and comparing said level to a standard.
Claim 2. The method of claim 1, wherein modulation of the level of at least one polypeptide biomarker which is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, SCF or a combination thereof in a patient post Regorafenib treatment is indicative of a response to Regorafenib.
Claim 3. The method according to claim 2, wherein said response is a reduction in tumor size.
Claim 4. The method according to claim 2, comprising detecting a combination of biomarkers.
Claim 5. The method according to claim 4, wherein said combination comprises at least one biomarker from PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, or ANG2 and at least one biomarker from sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF.
Claim 6. The method according to claim 4, comprising detecting sKIT, CYTC, CK18M30.
Claim 7. The method of claim 1, comprising detecting PLGF, CALX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, SCF or a combination thereof at the mRNA level in said Regorafenib-treated patient specimen and said control specimen.
Claim 8. The method of claim 7, wherein said mRNA level is detected by contacting said patient specimen with a polynucleotide which specifically binds to said mRNA and measuring the amount of the specifically bound agent.
Claim 9. The method of claim 1, comprising detecting PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, SCF or a combination thereof at the protein level in said Regorafenib-treated patient specimen and said control specimen.
Claim 10. The method of claim 9, wherein said patient specimen comprises a bodily fluid.
Claim 11. The method of claim 10, wherein said bodily fluid is blood.
Claim 12. A method of claim 9 wherein the cancer is renal carcinoma (RCC).
Claim 13. A method as in claim 9 wherein the cancer is
(a)a solid tumor of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid or their different metastases, (b) a lymphoma, (c) a sarcomas or (d) leukemia.
Claim 14. The method of claim 13, wherein
said cancer of breast cancer is: invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ;
said cancer of the respiratory tract is small-cell lung carcinoma, non-small-cell lung carcinoma, bronchial adenoma or pleuropulmonary blastoma;
said cancer of the brain is brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, neuroectodermal or pineal tumor; said cancer of the reproductive organ is prostate, testicular cancer, endometrial, cervical, ovarian, vaginal, vulvar cancer, or sarcoma of the uterus;
said cancer of the digestive tract is anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, or salivary gland cancer;
said cancer of the urinary tract is bladder, penile, kidney, renal, pelvic, ureterine, or urethral cancer;
said cancer of the eye is intraocular melanoma or retinoblastoma;
said cancer of the liver comprises hepatocellular carcinoma, cholangiocarcinoma, or mixed hepatocellular carcinoma; said cancer of the skin comprises squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, or non-melanoma skin cancer;
said cancer of the head-and-neck comprises laryngeal, hypopharyngeal, nasopharyngeal, or oropharyngeal cancer, lip cancer or oral cavity cancer;
said cancer of the blood comprises AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, lymphoma of the central nervous system, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, or hairy cell leukemia;
said sarcoma comprises sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, rhabdomyosarcoma, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, or hairy cell leukemia.
Claim 15. A method of claim 1 to monitor the response of a cancer patient to treatment with Regorafenib, comprising:
(a) determining the level of expression of at least one protein biomarker which is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF in a first biological sample taken from the patient prior to treatment with Regorafenib;
(b) determining the level of expression of at least one protein biomarker selected in step (a) in at least a second biological sample taken from the patient subsequent to the initial treatment with Regorafenib; and
(c) comparing the level of expression of said at least one biomarker which is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF in the first sample with the level of expression of the biomarker in the second sample; wherein a change in the level of expression of the PLGF, CArX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF in the second sample compared to the level of expression of said PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF in the first sample indicates the effectiveness of the treatment with Regorafenib.
Claim 16. A method as in claim 15 wherein an increase in the levels of said PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, or ANG2 and/or a decrease in the levels of said SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF in said patient compared to said reference standard is indicative of said response to Regorafenib treatment.
Claim 17. The method as in claim 16, wherein said response is a reduction in tumor size.
Claim 18. A method as in claim 15 wherein the biological sample is selected from blood, amniotic fluid, plasma, serum, semen, bone marrow, urine or tissue biopsy.
Claim 19. A method as in claim 15 wherein the biological sample is plasma.
Claim 20. A method as in claim 15 wherein the cancer is
(a)a solid tumor of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid or their different metastases, (b) a lymphoma, (c) a sarcomas or (d) leukemia.
Claim 21. The method of claim 20, wherein
said cancer of breast cancer is: invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ;
said cancer of the respiratory tract is small-cell lung carcinoma, non-small-cell lung carcinoma, bronchial adenoma or pleuropulmonary blastoma;
said cancer of the brain is brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, neuroectodermal or pineal tumor; said cancer of the reproductive organ is prostate, testicular cancer, endometrial, cervical, ovarian, vaginal, vulvar cancer, or sarcoma of the uterus;
said cancer of the digestive tract is anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, or salivary gland cancer;
said cancer of the urinary tract is bladder, penile, kidney, renal, pelvic, ureterine, or urethral cancer;
said cancer of the eye is intraocular melanoma or retinoblastoma;
said cancer of the liver comprises hepatocellular carcinoma, cholangiocarcinoma, or mixed hepatocellular carcinoma; said cancer of the skin comprises squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, or non-melanoma skin cancer;
said cancer of the head-and-neck comprises laryngeal, hypopharyngeal, nasopharyngeal, or oropharyngeal cancer, lip cancer or oral cavity cancer;
said cancer of the blood comprises AIDS-related lymphoma, non- Hodgkin' s lymphoma, cutaneous T-cell lymphoma, Hodgkin' s disease, lymphoma of the central nervous system, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, or hairy cell leukemia;
said sarcoma comprises sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, rhabdomyosarcoma, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, or hairy cell leukemia.
Claim 22. A method of claim 1 for monitoring the response of a patient being treated for solid tumors with the compound 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3- fluorophenoxy}-pyridine-2-carboxylic acid methylamide of the formula I below or pharmac ate or combination thereof
Figure imgf000048_0001
comprising: a) determining the level of expression of at least one protein biomarker which is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF in a first biological sample taken from a patient prior to treatment with the compound of formula I or a pharmaceutically acceptable salt, polymorph, hydrate, solvate or combination thereof;
b) determining the level of expression of at least one protein biomarker selected in step (a) in at least a second biological sample taken from the patient subsequent to the initial treatment with the compound of formula I or a pharmaceutically acceptable salt, polymorph, hydrate, solvate or combination thereof , and c) comparing the level of expression of said at least one biomarker which is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4 or SCF in the second sample with the level of expression of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF in the first sample;
wherein the change in level of expression of PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF in the second sample compared to the level of expression of said PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, sVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, or SCF in the first sample indicates the effectiveness in the treatment with the compound of formula I or a pharmaceutically acceptable salt, polymorph, hydrate, solvate or combination thereof.
Claim 23. A method as in claim 22 wherein the biological sample is blood, amniotic fluid, plasma, serum, semen, urine, bone marrow or a tissue biopsy.
Claim 24. A method as in claim 22 wherein the biological sample is plasma.
Claim 25. A method as in claim 22 wherein the cancer is renal cell carcinoma.
Claim 26. The method of claim 15, wherein said cancer is renal cell carcinoma.
Claim 27. A method of treating renal cell carcinoma comprising
a) determining and/or monitoring the response of a patient with renal cell carcinoma to Regorafenib, comprising detecting the level or activity of at least one polypeptide biomarker which is PLGF, CAIX, FASL, CYTC, CK18M30, VEGFA, VEGFD, ANG2, SVEGFR2, sKIT, sTIEl, bFGF, TIMP2, TIMP4, HGF, SCF or a combination thereof in a patient specimen and comparing said level to a standard and
b) administering Regorafenib to said patient following step (a).
PCT/US2011/037166 2010-05-19 2011-05-19 Biomarkers for a multikinase inhibitor WO2011146725A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34643310P 2010-05-19 2010-05-19
US61/346,433 2010-05-19

Publications (1)

Publication Number Publication Date
WO2011146725A1 true WO2011146725A1 (en) 2011-11-24

Family

ID=44121333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/037166 WO2011146725A1 (en) 2010-05-19 2011-05-19 Biomarkers for a multikinase inhibitor

Country Status (1)

Country Link
WO (1) WO2011146725A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102854322A (en) * 2012-07-31 2013-01-02 吴克 Vascular endothelial growth factor (VEGF) receptor enzyme linked diagnosis kit and preparation method thereof
CN105136956A (en) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 Method of rapidly determining regorafenib content
WO2017110764A1 (en) * 2015-12-24 2017-06-29 公益財団法人がん研究会 Test method for predicting effectiveness and safety of multi-kinase inhibitor, test kit, and biomarker
WO2017182985A1 (en) * 2016-04-20 2017-10-26 Morphotek, Inc. Prognosis of serous ovarian cancer using biomarkers
US9957232B2 (en) 2006-10-11 2018-05-01 Bayer Healthcare Llc 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
CN113533728A (en) * 2021-06-03 2021-10-22 中国科学院生物物理研究所 Biomarker of brain glioma and application thereof

Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5432049A (en) 1989-11-29 1995-07-11 Ciba-Geigy Corporation Photochromic composition
US5436327A (en) 1988-09-21 1995-07-25 Isis Innovation Limited Support-bound oligonucleotides
WO1995022058A1 (en) 1994-02-10 1995-08-17 Affymax Technologies N.V. Method and apparatus for detection of fluorescently labeled materials
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US5492806A (en) 1987-04-01 1996-02-20 Hyseq, Inc. Method of determining an ordered sequence of subfragments of a nucleic acid fragment by hybridization of oligonucleotide probes
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
EP0721016A2 (en) 1994-10-21 1996-07-10 Affymax Technologies N.V. Nucleic acid library arrays, methods for synthesizing them and methods for sequencing and sample screening using them
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
EP0728520A1 (en) 1995-02-27 1996-08-28 Affymax Technologies N.V. Printing molecular library arrays
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5561071A (en) 1989-07-24 1996-10-01 Hollenberg; Cornelis P. DNA and DNA technology for the construction of networks to be used in chip construction and chip production (DNA-chips)
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5580732A (en) 1992-04-03 1996-12-03 The Perkin Elmer Corporation Method of DNA sequencing employing a mixed DNA-polymer chain probe
WO1997002357A1 (en) 1995-06-29 1997-01-23 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
EP0785280A2 (en) 1995-11-29 1997-07-23 Affymetrix, Inc. (a California Corporation) Polymorphism detection
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
WO1997029212A1 (en) 1996-02-08 1997-08-14 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
EP0799897A1 (en) 1996-04-04 1997-10-08 Affymetrix, Inc. (a California Corporation) Methods and compositions for selecting tag nucleic acids and probe arrays
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5744305A (en) 1989-06-07 1998-04-28 Affymetrix, Inc. Arrays of materials attached to a substrate
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5848659A (en) 1993-04-02 1998-12-15 Mannesmann Aktiengesellschaft Non-railbound vehicle with an electric motor
US6022963A (en) 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
US6077674A (en) 1999-10-27 2000-06-20 Agilent Technologies Inc. Method of producing oligonucleotide arrays with features of high purity
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
WO2003097854A2 (en) * 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
WO2005009961A2 (en) 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US7833736B2 (en) 2006-03-31 2010-11-16 Cell Signaling Technology, Inc. Protein markers of responsiveness to type III receptor tyrosine kinase inhibitors

Patent Citations (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5492806A (en) 1987-04-01 1996-02-20 Hyseq, Inc. Method of determining an ordered sequence of subfragments of a nucleic acid fragment by hybridization of oligonucleotide probes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5436327A (en) 1988-09-21 1995-07-25 Isis Innovation Limited Support-bound oligonucleotides
US5405783A (en) 1989-06-07 1995-04-11 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of an array of polymers
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5770456A (en) 1989-06-07 1998-06-23 Affymetrix, Inc. Cyclic nucleic acid and polypeptide arrays
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5744305A (en) 1989-06-07 1998-04-28 Affymetrix, Inc. Arrays of materials attached to a substrate
US5510270A (en) 1989-06-07 1996-04-23 Affymax Technologies N.V. Synthesis and screening of immobilized oligonucleotide arrays
US5445934A (en) 1989-06-07 1995-08-29 Affymax Technologies N.V. Array of oligonucleotides on a solid substrate
US5561071A (en) 1989-07-24 1996-10-01 Hollenberg; Cornelis P. DNA and DNA technology for the construction of networks to be used in chip construction and chip production (DNA-chips)
US5432049A (en) 1989-11-29 1995-07-11 Ciba-Geigy Corporation Photochromic composition
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5885837A (en) 1991-11-22 1999-03-23 Affymetrix, Inc. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5580732A (en) 1992-04-03 1996-12-03 The Perkin Elmer Corporation Method of DNA sequencing employing a mixed DNA-polymer chain probe
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5848659A (en) 1993-04-02 1998-12-15 Mannesmann Aktiengesellschaft Non-railbound vehicle with an electric motor
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5529756A (en) 1993-10-22 1996-06-25 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
WO1995022058A1 (en) 1994-02-10 1995-08-17 Affymax Technologies N.V. Method and apparatus for detection of fluorescently labeled materials
US5856101A (en) 1994-05-24 1999-01-05 Affymetrix, Inc. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5593839A (en) 1994-05-24 1997-01-14 Affymetrix, Inc. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
EP0721016A2 (en) 1994-10-21 1996-07-10 Affymax Technologies N.V. Nucleic acid library arrays, methods for synthesizing them and methods for sequencing and sample screening using them
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5770722A (en) 1994-10-24 1998-06-23 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
EP0728520A1 (en) 1995-02-27 1996-08-28 Affymax Technologies N.V. Printing molecular library arrays
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5919523A (en) 1995-04-27 1999-07-06 Affymetrix, Inc. Derivatization of solid supports and methods for oligomer synthesis
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5874219A (en) 1995-06-07 1999-02-23 Affymetrix, Inc. Methods for concurrently processing multiple biological chip assays
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
WO1997002357A1 (en) 1995-06-29 1997-01-23 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
EP0785280A2 (en) 1995-11-29 1997-07-23 Affymetrix, Inc. (a California Corporation) Polymorphism detection
US6022963A (en) 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
WO1997029212A1 (en) 1996-02-08 1997-08-14 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
EP0799897A1 (en) 1996-04-04 1997-10-08 Affymetrix, Inc. (a California Corporation) Methods and compositions for selecting tag nucleic acids and probe arrays
US6077674A (en) 1999-10-27 2000-06-20 Agilent Technologies Inc. Method of producing oligonucleotide arrays with features of high purity
WO2003097854A2 (en) * 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
WO2005009961A2 (en) 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US20050038080A1 (en) 2003-07-23 2005-02-17 Stephen Boyer Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US7833736B2 (en) 2006-03-31 2010-11-16 Cell Signaling Technology, Inc. Protein markers of responsiveness to type III receptor tyrosine kinase inhibitors

Non-Patent Citations (69)

* Cited by examiner, † Cited by third party
Title
"PCR Protocols: A Guide to Methods and Applications", 1990, ACADEMIC PRESS
"PCR Technology: Principles and Applications for DNA Amplification", 1992, FREEMAN PRESS
"PCR", IRL PRESS
ANDERBERG: "Cluster Analysis for Applications", 1973, ACADEMIC PRESS
ARNHEITER ET AL., NATURE, vol. 294, 1981, pages 278
BART C KUENEN ET AL: "Efficacy and Toxicity of the Angiogenesis Inhibitor SU5416 As a Single Agent in Patients with Advanced Renal Cell Carcinoma, Melanoma, and Soft Tissue Sarcoma", CLIN CANCER RES 2003;9, 1 May 2003 (2003-05-01), pages 1648 - 1655, XP055008131, Retrieved from the Internet <URL:http://clincancerres.aacrjournals.org/content/9/5/1648.full.pdf> [retrieved on 20110927] *
BEAUCAGE, CARRUTHERS, TETRAHEDRON LETT., vol. 22, 1981, pages 1859 - 62
BERTUCCI ET AL., HUM. MOL. GENET., vol. 8, 1999, pages 2129
BISWAS ET AL., ANN. NY ACAD. SCI., vol. 590, 1990, pages 582 - 583
BISWAS ET AL., J. CLIN. MICROBIOL., vol. 29, 1991, pages 2228 - 2233
BLANCHARD ET AL., BIOSENSORS AND BIOELECTRONICS, vol. 11, 1996, pages 687 - 90
BOERSMA, VAN LEEUWEN, J. NEUROSCI. METHODS, vol. 51, 1994, pages 317
BONNER ET AL., SCIENCE, vol. 278, 1997, pages 1481
BOWTELL ET AL., NAT. GENET., vol. 21, 1999, pages 25
CHIRGWIN ET AL., BIOCHEMISTRY, vol. 18, 1979, pages 5294 - 5299
DIEFFENBACH, DVEKSLER: "PCR Primer, A Laboratory Manual", 1995, COLD SPRING HARBOR PRESS
DUGGAN ET AL., NAT. GENET., vol. 21, 1999, pages 10
DULAC, CURR. TOP. DEV. BIOL., vol. 36, 1998, pages 245
DYMECKI ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 4815
E. MAGGIO: "Enzyme-Immunoassay", 1980, CRC PRESS, INC.
EBERWINE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 3010
ECKERT ET AL.: "PCR Methods and Applications", vol. 1, 1991, pages: 17
EISEN T ET AL: "7105 Phase II trial of the oral multikinase inhibitor BAY 73-4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC)", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 7, no. 2, 1 September 2009 (2009-09-01), pages 424, XP026628561, ISSN: 1359-6349, [retrieved on 20090901], DOI: DOI:10.1016/S1359-6349(09)71438-7 *
EMMERT-BUCK ET AL., SCIENCE, vol. 274, 1996, pages 998
EVERITT: "Cluster Analysis", 1974, HEINEMANN EDUC. BOOKS
FEND ET AL., AM. J. PATH., vol. 154, 1999, pages 61
FROST ET AL.: "Phase I Study of BAY 73-4506, an Inhibitor of Oncogenic and Angiogenic Kinases", PATIENTS WITH ADVANCED SOLID TUMORS: FINAL RESULTS OF A DOSE-ESCALATION STUDY, 2008
FUKUNAGA: "Statistical Pattern Recognition", 1990, ACADEMIC PRESS
GREEN ET AL., CELL, vol. 28, 1982, pages 477
GRESS ET AL., MAMMALIAN GENOME, vol. 3, 1992, pages 609
GUATELLI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1874
HARTIGAN: "Clustering Algorithms", 1975, WILEY
HEGDE ET AL., BIOTECHNIQUES, vol. 29, 2000, pages 548
HUGHES ET AL., NAT. BIOTECHOL., vol. 19, 2001, pages 342
JEFFERS ET AL: "Identification of plasma biomarkers for the multikinase inhibitor regorafenib (BAY 73-4506) in patients (pts) with renal cell cancer (RCC)", ESMO 2010, 19 May 2010 (2010-05-19), XP055003948 *
JENA ET AL., J. IMMUNOL. METHODS, vol. 190, 1996, pages 199
KACHARMINA ET AL., METH. ENZYMOL., vol. 303, 1999, pages 3
KIES ET AL.: "Phase I study of Regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC", J CLIN ONCOL (MEETING ABSTRACTS, vol. 28, no. 15, 2010
KIM ET AL., J. VIROL., vol. 66, 1992, pages 3879 - 3882
KRICKA: "Nonisotopic DNA Probe Techniques", 1992, ACADEMIC PRESS
KWOH ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 1173
LANDEGREN ET AL., SCIENCE, vol. 241, 1988, pages 1077
LENNON ET AL., TRENDS GENET., vol. 7, 1991, pages 314
LIPSHUTZ ET AL., NATURE GENET., vol. 21, 1999, pages 20 - 24
LIVESEY ET AL., CURR. BIOL., vol. 10, 2000, pages 301
LUO ET AL., NAT. MED., vol. 5, 1999, pages 117
MASKOS ET AL., NUCLEIC ACIDS RES., vol. 21, 1993, pages 4663 - 69
MATTEUCCI ET AL., J. AM. CHEM. SOC., vol. 103, 1981, pages 3185
MATTILA ET AL., NUCLEIC ACIDS RES., vol. 19, 1991, pages 4967
MURAKAMI ET AL., KIDNEY INT., vol. 58, 2000, pages 1346
NGUYEN ET AL., GENOMICS, vol. 29, 1995, pages 207
OHYAMA ET AL., BIOTECHNIQUES, vol. 29, 2000, pages 530
SAKAI ET AL., ANAL. BIOCHEM., vol. 287, pages 2000
SCOTT M. WILHELM ET AL: "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity", INTERNATIONAL JOURNAL OF CANCER 129, 17 December 2010 (2010-12-17), pages 245 - 255, XP055003945, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1002/ijc.25864/asset/25864_ftp.pdf?v=1&t=gqt733ug&s=e6d59b5458c6f2d15a7a835aab2155a08e75a323> [retrieved on 20110801], DOI: 10.1002/ijc.25864 *
SHALON ET AL., GENOME RES., vol. 6, 1996, pages 639 - 645
SHENA ET AL., SCIENCE, vol. 270, 1995, pages 467 - 470
SHENA ET AL., TIBTECH, vol. 16, 1998, pages 301
SNEATH, SOKAL: "Numerical Taxonomy", 1973, FREEMAN
SPIRIN ET AL., INVEST. OPHTALMOL. VIS. SCI., vol. 40, 1999, pages 3108
STRUMBERG ET AL.: "Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC", J CLIN ONCOL (MEETING ABSTRACTS, vol. 27, no. 15S, 2009, pages 161S
THIEL ET AL., ANAL. CHEM., vol. 69, 1997, pages 4948
TIJSSEN ET AL.: "Laboratory Techniques in Biochemistry and Molecular Biology", vol. 24, 1993, ELSEVIER, article "Hybridization With Nucleic Acid Probes"
TYAGI, KRAMER, NATURE BIOTECH., vol. 14, 1996, pages 303
WANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 9717
WU, WALLACE, GENOMICS, vol. 4, 1989, pages 560
ZHAO ET AL., GENE, vol. 156, pages 207
ZHUMABAYEVA ET AL., BIOTECHNIQUES, vol. 30, 2001, pages 158
ZOPF ET AL.: "Regorafenib (BAY 73-4506): identification of clinically relevant metabolites and their preclinical pharmacology", 101ST AACR ANNUAL MEETING, 17 April 2010 (2010-04-17)
ZUPPI ET AL., CLIN CHIM ACTA, vol. 265, 1997, pages 85 - 97

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9957232B2 (en) 2006-10-11 2018-05-01 Bayer Healthcare Llc 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
CN102854322A (en) * 2012-07-31 2013-01-02 吴克 Vascular endothelial growth factor (VEGF) receptor enzyme linked diagnosis kit and preparation method thereof
CN105136956A (en) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 Method of rapidly determining regorafenib content
WO2017110764A1 (en) * 2015-12-24 2017-06-29 公益財団法人がん研究会 Test method for predicting effectiveness and safety of multi-kinase inhibitor, test kit, and biomarker
JPWO2017110764A1 (en) * 2015-12-24 2018-11-01 公益財団法人がん研究会 Test method, test kit, and biomarker for predicting efficacy and safety of multikinase inhibitor
WO2017182985A1 (en) * 2016-04-20 2017-10-26 Morphotek, Inc. Prognosis of serous ovarian cancer using biomarkers
CN113533728A (en) * 2021-06-03 2021-10-22 中国科学院生物物理研究所 Biomarker of brain glioma and application thereof

Similar Documents

Publication Publication Date Title
US20070178494A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US8329408B2 (en) Methods for prognosis and monitoring cancer therapy
EP1945819B1 (en) Gene expression profiles and methods of use
EP1603514A2 (en) Expression profiles for colon cancer and methods of use
US20070065827A1 (en) Gene expression profiles and methods of use
WO2007123722A2 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2005032495A2 (en) Gene expression profiles and methods of use
EP1605811A2 (en) Expression profiles for breast cancer and methods of use
WO2011146725A1 (en) Biomarkers for a multikinase inhibitor
US20070134670A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20040121375A1 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2006032009A2 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2005067650A2 (en) Gene expression profiles and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11722691

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11722691

Country of ref document: EP

Kind code of ref document: A1